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Abstract 
CD4+ T cells are critical regulators of adaptive immune responses. CD4+ T cell activation is initiated and 
shaped by CD4+ T cell receptor (TCR) recognition of cognate peptide/major histocompatibility complex II 
(MHCII) complexes on the surface of antigen presenting cells (APCs). MHCII presentation of antigenic 
peptides has historically been viewed as a property restricted to a subset of immune cells deemed 
“professional” APCs – dendritic cells, macrophages, and B cells – that constitutively express MHCII. 
However, recently it has been demonstrated that various other immune and non-immune cell types can 
express MHCII, and that these “atypical” APCs make essential contributions to the regulation of CD4+ T 
cell responses in the periphery. In the distal lung, type II alveolar cells (AT2s), epithelial cells whose main 
functions are to produce surfactant and facilitate lung regeneration, have also been reported to express 
MHCII at homeostasis. However, the contribution of AT2 MHCII to lung adaptive immune responses, and 
the factors driving its expression, are unknown. Here we explore both the regulation and function of 
MHCII on AT2s. First, we demonstrate that AT2s constitutively express high levels of MHCII in a manner 
that does not require induction by inflammatory stimuli, making them unique among all other previously 
studied non-immune cells. Using mouse models, we also demonstrate that AT2 MHCII participates in lung 
immune responses in vivo. At homeostasis, aged mice lacking AT2 MHCII have lower frequencies of lung 
T cells with an antigen-experienced phenotype. Furthermore, following respiratory viral infection, the 
absence of AT2 MHCII results in increased morbidity and mortality. In both of these settings, the 
contribution of AT2 MHCII is moderate. Consistent with this more modest impact, we find that AT2s 
demonstrate a globally limited capacity to present antigen via MHCII. We propose that the combination of 
high MHCII expression with restrained MHCII antigen presentation enables AT2s to contribute to lung 
immune responses in a more measured fashion, preventing excessive inflammation that would be 
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THE REGULATION AND FUNCTION OF MAJOR HISTOCOMPATIBILITY 
COMPLEX II ON LUNG TYPE II ALVEOLAR CELLS 
 
Sushila A. Toulmin 
Laurence C. Eisenlohr 
 
CD4+ T cells are critical regulators of adaptive immune responses. CD4+ T cell 
activation is initiated and shaped by CD4+ T cell receptor (TCR) recognition of cognate 
peptide/major histocompatibility complex II (MHCII) complexes on the surface of 
antigen presenting cells (APCs). MHCII presentation of antigenic peptides has 
historically been viewed as a property restricted to a subset of immune cells deemed 
“professional” APCs – dendritic cells, macrophages, and B cells – that constitutively 
express MHCII. However, recently it has been demonstrated that various other 
immune and non-immune cell types can express MHCII, and that these “atypical” 
APCs make essential contributions to the regulation of CD4+ T cell responses in the 
periphery. In the distal lung, type II alveolar cells (AT2s), epithelial cells whose main 
functions are to produce surfactant and facilitate lung regeneration, have also been 
reported to express MHCII at homeostasis. However, the contribution of AT2 MHCII 
to lung adaptive immune responses, and the factors driving its expression, are 
unknown. Here we explore both the regulation and function of MHCII on AT2s. First, 
we demonstrate that AT2s constitutively express high levels of MHCII in a manner that 
does not require induction by inflammatory stimuli, making them unique among all 
other previously studied non-immune cells. Using mouse models, we also 
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demonstrate that AT2 MHCII participates in lung immune responses in vivo. At 
homeostasis, aged mice lacking AT2 MHCII have lower frequencies of lung T cells 
with an antigen-experienced phenotype. Furthermore, following respiratory viral 
infection, the absence of AT2 MHCII results in increased morbidity and mortality. In 
both of these settings, the contribution of AT2 MHCII is moderate. Consistent with this 
more modest impact, we find that AT2s demonstrate a globally limited capacity to 
present antigen via MHCII. We propose that the combination of high MHCII expression 
with restrained MHCII antigen presentation enables AT2s to contribute to lung immune 
responses in a more measured fashion, preventing excessive inflammation that would 
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CHAPTER 1:  
GENERAL INTRODUCTION 
 
1.1 Introduction to the immune system 
The mammalian immune system is composed of an extensive network of 
cells, as well as intracellular, cell-surface, and secreted molecules. Exquisitely 
precise coordination of all of these factors is required for the appropriate recognition 
of foreign substances and the execution of robust, yet regulated, defenses against 
them. Both the failure to identify harmful substances and the inappropriate 
recognition of harmless or host-derived molecules as foreign can result in disease; 
similarly, effector responses that are inadequate, as well as responses that are too 
strong and uncontrolled, can both be damaging. The immune system must therefore 
constantly maintain a fine balance and does so by integrating multiple layers of 
countless cellular and molecular inputs. 
Immune responses can be broadly classified into two main classes: innate 
and adaptive [1]. Innate immune responses are initiated quickly, within hours of 
exposure a harmful stimulus. They are classically associated with barrier sites of 
continuous pathogen exposure, such as the skin, lung, or gut, and they are targeted 
against broadly conserved pathogen or tissue damage associated motifs. In 
contrast, adaptive immune responses are slower, developing over the course of 
days, but are much more precisely targeted against the specific offending infectious 
agent. Adaptive immune responses are also unique in that they generate 
immunological memory, such that upon re-exposure to the same specific pathogen, 
responses will be faster and more robust. During host responses to many infections, 
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such as viruses, both innate and adaptive immune responses represent sequential 
and integrated phases of host defense. This dissertation primarily addresses the 
adaptive component of antiviral host immune responses. 
By far the most well studied cell types involved in the orchestration of 
adaptive immune responses are conventional immune cells, which are derived from 
hematopoietic stem cells (HSCs) in the bone marrow. Out of the many different 
hematopoietic immune cell types, this dissertation explores the functions of the 
classical antigen-presenting cells (APCs), which include dendritic cells (DCs), B 
cells, and macrophages, and their interactions with one of the main adaptive immune 
cell lineages, CD4+ T cells.   
The contributions of all other cell types, ie: those that are not derived from 
HSCs, to adaptive immune responses are far less well understood. One notable 
exception is thymic epithelial cells (TECs), nonhematopoietic cells of the thymus that 
have been well studied for their critical function in T cell development. Otherwise, the 
role that other “non-immune” cells of the body, such as those that compose 
functional organs and tissues, may play in adaptive immune responses has 
historically not been the subject of extensive investigation. In this thesis I focus on 
the contribution of one particular non-immune cell type, the lung type II alveolar cell 




1.2 T cell responses in antiviral adaptive immunity  
T cells and B cells represent the two main arms of adaptive immune effector 
responses. Here, I detail the general functions of T cells, with particular attention to 
the CD4+ T cell lineage. 
CD4+ T “helper” (Th) cells play a central role in coordinating essentially all 
adaptive immune responses. Their main effector functions are to secrete instructive 
cytokines and to provide stimulatory signals to potentiate and alter the functions of 
other immune cell types. CD4+ T cells can adopt a number of different helper 
phenotypes that are each optimal for a distinct immune context. Major CD4+ Th 
phenotypes include Th1 that predominates during viral infections, Th2 during allergic 
and helminth responses,Th17 during responses to extracellular pathogens, as well 
as T follicular helper (Tfh) cells that are specialized for B cell help and regulatory T 
(Treg) cells that contribute to immunosuppressive responses [2]. During lung viral 
infections, CD4+ T cells mainly adopt a type 1 (Th1) phenotype that enhances the 
antiviral immune response. These cells secrete effector cytokines (IFN-γ, TNF-α, IL-
2), help B cells to produce high-affinity neutralizing antibodies, enhance CD8+ T cell 
cytolysis of infected cells and memory formation, and in some cases are directly 
cytolytic [3]. In these cases, a different CD4+ T cell phenotype-driven response, such 
as Th2, worsens disease by enhancing immunopathology in the lung [4, 5]; thus, the 
development of appropriate Th function is critical. The mechanisms governing CD4+ 
T cell activation and differentiation are detailed in the subsequent sections.   
Unlike CD4+ T cells, CD8+ T cells do not adopt such distinct phenotypes to 
the same extent, but they nonetheless also play critical roles in immune responses 
via their cytolytic function. During viral infections, their main functions are to secrete 
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effector cytokines, primarily IFN-γ and TNF-α, and to eliminate infected cells directly 
via the delivery of perforin and granzymes to the infected cell [6]. 
 
 
1.3 The T cell – APC interaction  
CD4+ T cells are activated by T cell receptor (TCR) recognition of antigenic 
protein-derived peptides bound to major histocompatibility complex II (MHCII) 
proteins on the surface of APCs. The activation of naïve T cells, or “priming”, occurs 
in secondary lymphoid organs, such as lymph nodes, and is mediated by a 
professional APC, usually a DC. Aside from recognition of a particular peptide/MHCII 
complex, activation of a naïve T cell is also thought to require a second 
costimulatory signal. This “signal 2” is typically provided by APC-derived CD80 or 
CD86 binding to CD28 on the T cell surface, and its absence results in T cell anergy 
rather than activation [1, 7-9]. The functional outcome of CD4+ T cell activation is 
further influenced by specific cytokine signals provided by the APC at the time of 
activation [2]. Altogether, the cytokine milieu present, in combination with 
costimulatory signals as well as the strength and duration of the peptide/MHCII 
interaction [10, 11], dictates the activation and Th phenotype that will be adopted by 
the CD4+ T cell. CD8+ T cell activation occurs in a similar manner, although the CD8+ 
T cell TCR recognizes specific peptide/MHCI complexes (not MHCII).   
After T cell activation occurs, effector T cells proliferate, then exit the lymph 
nodes and traffic to the site of injury or infection. Effector T cell activation is further 
modulated in the periphery by interaction with cognate peptide/MHC expressing cells 
that express a diverse array of additional costimulatory molecules, inhibitory receptor 
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ligands, and adhesion molecules, which may serve to re-expand or suppress T cells 
[7, 8, 12-14]. The phenotypic function of CD4+ T cells may also be altered in tissues 
by peripheral MHCII-expressing cells and changes in the cytokine environment, 
although the true plasticity of Th phenotypes is not fully understood [15, 16]. 
As recognition of specific peptide in the context of MHCII is a critical 
requirement for both CD4+ T cell priming and downstream regulation in the 
periphery, a major emphasis of this work is to understand how the formation of these 
peptide/MHCII complexes is regulated. This includes understanding how antigenic 
peptides are generated from source proteins and delivered to MHCII molecules, as 
well as how MHCII protein expression is restricted in a cell-type specific manner. 
 
 
1.4 Pathways of MHCII antigen processing and presentation 
There are a variety of pathways by which peptides may be generated and 
loaded onto MHCII. These pathways can be broadly classified based on whether 
they use extracellular or intracellular proteins as initial substrates. 
MHCII presentation of peptides derived from extracellular proteins has 
historically been the most well studied and characterized by far. In the “classical” 
pathway of exogenous MHCII presentation, extracellular protein is first taken up by 
an APC into an endocytic compartment [17]. Protein degradation then occurs in the 
endosomal network, with the final peptides being generated in the late endosome 
[18]. Nascent MHCII molecules are synthesized in the endoplasmic reticulum (ER) 
and are composed of one a and one b chain [18]. In the ER, these MHCII 
heterodimers associate with the chaperone protein invariant chain, which stabilizes 
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MHCII and helps it traffic to the late endosomal compartment [19-21]. In the late 
endosome, invariant chain is degraded by cathepsin proteases into the class II-
associated invariant chain peptide (CLIP), which remains in the MHCII peptide 
binding groove [22-26]. Another chaperone protein, H2M, then facilitates the removal 
of CLIP, which then allows the binding of antigenic peptides [27-30]. Peptide/MHCII 
complexes then traffic to the cell surface [17, 18].  
Deviations from the classical pathway of MHCII presentation that still rely on 
the uptake of extracellular antigen include different locations of peptide generation 
and loading. One alteration involves the generation of peptides that bind to MHCII 
molecules in the early endosome rather than the late endosome; this scenario also 
differs in that the source of MHCII is primarily recycling MHCII from the cell surface, 
rather than de novo synthesized MHCII, and that peptide loading can be either H2M 
dependent or independent [31-34]. This is most likely predominant for epitopes that 
would be otherwise fully degraded by the harsher pH and proteolytic environments of 
the late endosome or for scenarios in which MHCII biosynthesis is halted. Another 
alternative to the classical pathway is the loading of pre-formed extracellular 
peptides. While the loading of synthetic peptides is commonly used as an in vitro 
laboratory experimental tool, there is also evidence that extracellular processing and 
loading occurs in vivo [35-38]. Whether these peptides directly displace other MHCII-
bound peptides on the cell surface or require internalization for loading is still unclear 
[39, 40].  
Apart from the MHCII presentation of extracellularly acquired antigen, MHCII 
molecules also efficiently present peptides derived from intracellularly produced 
proteins. Although this property was demonstrated more than 30 years ago [41-45], 
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and has been demonstrated to be the predominant mechanism of epitope generation 
in certain settings, such as influenza virus infections [46], comparatively little 
attention has been paid to understanding the mechanisms by which endogenous 
MHCII processing and presentation occur. Studies that have explored these 
mechanisms demonstrate that a highly complex system of intracellular machinery is 
involved, which spans multiple subcellular compartments and can include factors 
such as cytosolic proteases, lysosomal enzymes, and the macroautophagy pathway 
[46-51]; however, the precise processing mediators required differ depending on the 
particular epitope produced. Because of this complexity, and the relative lack of 
mechanistic work in this area, the exact cellular factors required for the MHCII 
presentation of intracellular antigens are far less well characterized compared to 
classical MHCII presentation of exogenous antigen and seem to represent more of a 
“network” rather than one linear pathway. Nonetheless, one prerequisite for all 
endogenous processing and presentation is that, by definition, proteins must be 
synthesized de novo inside an APC. Thus, these protein substrates include host 
proteins as well as intracellularly produced pathogen-derived proteins, such as viral 
proteins synthesized within directly infected cells.  
The wide variety of methods by which peptides may be generated and loaded 
onto MHCII diversifies the potential repertoire of MHCII-restricted peptides that can 
be presented by APCs. Furthermore, as there is no one strict set of machinery 
required for the generation of all epitopes, this suggests that MHCII antigen 
processing can be performed by a variety of different MHCII-expressing cell types, 
with each APC type using its own unique cohort of cellular mediators. This 
maximizes the likelihood that an MHCII-expressing cell type will be capable of 
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presenting antigen, but also suggests that there is substantial variability in antigen 
presentation capacity among candidate APCs both in aggregate and on an epitope-
specific basis. Such complexity also suggests that there are numerous points where 
epitope generation and presentation may be regulated.  
 
 
1.5 The regulation of MHCII expression 
Transcription of MHCII is driven by the class II transactivator (CIITA), a non-
DNA-binding co-activator. CIITA initiates transcription by binding to a ubiquitously 
expressed protein complex (composed of RFX, CREB/ATF, and NF-Y), which then 
binds to a conserved promoter-proximal enhancer SXY element upstream of the 
MHCII a and b chain gene loci [52]. CIITA then recruits chromatin remodeling 
complexes and the transcriptional machinery to facilitate gene expression, and may 
facilitate long-range promoter interactions to enhance expression as well [52, 53].  
As the SXY module is also present upstream of the MHCII associated genes 
encoding the invariant chain, H2M, and the H2M-antagonist H2O, expression of 
these genes is coregulated along with MHCII by CIITA [54]. Although CHIP-seq, 
ATAC-seq, and DNAse hypersensitivity studies have demonstrated that CIITA is 
also present at hundreds of other locations within the genome that are not typically 
associated with MHCII, it is unclear to what extent this translates into true 
transcriptional regulation and whether these targets require CIITA binding for 
transcription [55-57]. 
Unlike most other genes, which rely on combinatorial transcription factor 
binding to modulate transcription, the transcription of MHCII is essentially exclusively 
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controlled by CIITA. Thus, MHCII expression is regulated by the mechanisms that 
regulate the transcription and expression of CIITA.   
Transcription of CIITA begins at three distinct promoter sites within the CIITA 
locus: pI, pIII, and pIV. Transcriptional initiation occurs at each promoter in response 
to different cell-type and context-specific stimuli. By convention, homeostatic 
recruitment of pI occurs in conventional DCs and macrophages, and pIII in B cells 
and plasmacytoid DCs, while CIITA pIV is recruited in nonhematopoietic cell types in 
response to the inflammatory cytokine IFNg [58]. Thus, it is thought that DCs, 
macrophages, and B cells express MHCII constitutively, while nonhematopoietic 
cells only do so in the setting of inflammation. However, there are an increasing 
number of notable exceptions to this paradigm, as discussed in 1.7. The three 
transcripts produced from pI, pIII, and pIV each differ in their first exon, and the 
resulting proteins at their N termini, but all are thought to function similarly in 
inducing expression of MHCII and associated genes [58]. 
Apart from the CIITA-induced transcription and expression of MHCII, cells 
may also acquire MHCII protein from extrinsic sources. There are three main 
mechanisms by which has been described to occur [59]. The first is by trogocytosis, 
a process in which direct cell-to-cell contact facilities the transfer of membranes 
rapidly between two cells [60, 61]; in this case the transferred membrane would 
contain MHCII proteins. The second is by exosome-mediated transfer, whereby an 
MHCII+ cell releases small membrane vesicles [62] carrying MHCII molecules, that 
are then taken up by a recipient cell [63]. The third is via tunneling nanotubes, or 
long membrane protrusions that enable the transfer of cytoplasmic material as well 
as cell surface molecules between cells [64, 65].  
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1.6 The professional APCs and the requirements of an APC  
Historically, MHCII antigen presentation has been studied as a property 
restricted to the group of cells termed “professional APCs”: B cells, macrophages, 
and DCs. A defining feature of this group is that, as discussed above, these cell 
types express MHCII at homeostasis by virtue of constitutive CIITA expression. 
Another key hallmark is that they are each highly specialized for the processing and 
presentation of antigen via MHCII, with particularly well-developed mechanisms of 
antigen uptake, degradation, and MHCII loading [17]. For example, circulating DCs 
exhibit robust macropinocytosis, which allows them to continuously sample and take 
up a wide variety of potential antigens that could be presented via MHCII [17, 66]. 
DCs are also highly phagocytic, as are macrophages [17, 67]. Furthermore, B cells 
exhibit extremely efficient endocytic uptake of proteins for which their B cell 
receptors (BCR) are specific [68-70].  The subcellular compartments of all three cell 
types are also uniquely tailored to MHCII antigen presentation; they contain an 
assortment of critical antigen processing and presentation enzymes and 
chaperones, and they are dynamically regulated in response to environmental cues 
to either promote or inhibit the presentation of antigens via MHCII [17, 69, 71-74].  
However, as discussed above, besides the professional APCs, a variety of 
other cell types express MHCII in response to IFNg induction of CIITA pIV (and in 
other scenarios [to be discussed in 1.7]). Therefore, a better understanding of 
whether these “non-professional” MHCII-expressing cells can also act as APCs, and 
the possible contributions they might make as a result, is warranted. To this end, I 
begin by summarizing the key “required” features of an APC that would endow a 
non-professional MHCII+ cell with MHCII antigen presentation capacity. 
 11 
(1) The first requirement is antigen uptake. As discussed in 1.4, MHCII molecules 
can present antigen from either intracellular or extracellular protein sources. 
Thus, all cell types should be capable of this “antigen uptake” step in general to 
some degree, as all cells express their own intracellular proteins. For the 
presentation of a peptide from a specific protein, this would necessitate that the 
cell could take up the protein of interest into the endocytic pathway from the 
extracellular space, or that the cell produce the specific protein de novo, either a 
self-protein or a pathogen protein when directly infected.  
(2) After antigen uptake, appropriate proteolysis and peptide transport would be 
required. Thus, the cell must express enzymes capable of protein degradation, 
but also possess a proteolytic environment that is not so harsh that all epitopes 
are destroyed before the possibility of loading onto MHCII [75-77]. Most cells 
possess this capability to some degree, although the precise proteases and 
protein processing enzymes expressed varies considerably between cell types. 
As discussed in 1.4, the specific degradative enzymes required are epitope 
dependent; thus, for the MHCII presentation of a specific epitope of interest, a 
cell would have to express the suite of enzymes required for generation of that 
particular peptide. Apart from the capacity to generate peptide fragments, a cell 
would also need to have appropriate transporters or vesicular trafficking and 
maturation to allow the peptides to reach the MHCII loading compartments, 
depending on where the peptide is initially generated and where it is loaded 
onto MHCII. 
(3) A third critical property is the appropriate stabilization and trafficking of MHCII 
to the peptide loading compartment. By convention, this is accomplished by the 
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chaperone protein invariant chain [19-21]. However, cells from invariant chain 
deficient mice still express appreciable levels of surface MHCII, although they 
are reduced relative to their wild-type counterparts (Fig 1.1). Thus, while 
expression of invariant chain likely enhances presentation by a cell, it is not 
absolutely required for MHCII stabilization or trafficking, or for presentation [78, 
79].  
(4) The next step required for antigen presentation is peptide binding to MHCII. In 
the classical model of MHCII presentation, this requires the peptide-loading 
chaperone H2M, which unloads CLIP from the MHCII peptide-binding groove in 
the late endosome, allowing for the loading of other peptides. However, H2M is 
more accurately described as a peptide “editor” that exchanges lower affinity 
peptides for higher affinity ones. Thus, only some peptides are favored by 
and/or require the presence of H2M, such as those with (i) high affinity for 
MHCII, (ii) those restricted by MHCII molecules with high affinity for CLIP, or 
(iii) those loaded in the late endosome, where H2M is more abundant. Peptides 
that have low affinity for MHCII, are loaded in other compartments (such as the 
early endosome), or bind to MHCII molecules that have a low affinity for CLIP, 
 
Figure 1.1: Invariant chain deficient mouse DCs express MHCII. MHCII protein expression by 
CD103+ DCs from naïve C57Bl/6 (B6) wild-type (WT), invariant chain deficient (Cd74-/-), and 

















do not require H2M for loading onto MHCII and can actually be “edited out” by 
H2M when it is present. Thus, H2M is not required for the loading of all MHCII-
restricted epitopes, and the presence of H2M actually hinders the presentation 
of some peptides [30, 46, 80-85]. 
In summary, the defining characteristics of a putative MHCII+ APC – antigen uptake, 
measured proteolysis, appropriate peptide and MHCII trafficking, and peptide 
loading – are quite flexible in how they can be accomplished, and thus could be 
theoretically fulfilled by most MHCII+ cell types in a general sense. However, MHCII 
presentation capacity likely does not operate on this yes-or-no basis but instead 
represents a spectrum from inefficient (less active antigen uptake, fewer proteolytic 
enzymes, no chaperone expression) to highly efficient like that of professional APCs 
(robust endocytosis, full suite of processing enzymes, both H2M and invariant chain 
are expressed). Furthermore, inefficient versus efficient MHCII presentation capacity 
can be interpreted on a global level (few versus many epitopes presented) or in 
relation to one epitope in particular (low versus high levels of specific peptide/MHCII 
complex formation).  
Furthermore, although not required for MHCII presentation capacity, another 
important APC feature that would fine-tune the function of a putative APC is the 
expression of costimulatory molecules [7]. For example, expression of the 
conventional costimulatory molecules CD80 or CD86 alongside peptide/MHCII 
complexes would render a cell capable of priming a cognate naïve CD4+ T cell; the 
absence of CD80/CD86 would instead suggest a role for the APC inducing naïve 
CD4+ T cell tolerance [8, 9]. Expression of other non-canonical costimulatory 
molecules, such as ICAM-1, would allow the APC to promote the activation of 
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effector CD4+ T cells, whereas expression of inhibitory receptors, such as PD-L1, 
would enable the suppression of CD4+ T cell effector functions by the APC [12-14, 
86]. The regulated expression of a broad array of these costimulatory molecules 
would endow an APC with the capacity to interact with CD4+ T cells in a fine-tuned 
manner, providing activating or inhibitory cues depending upon the immunologic 
context. 
Overall, it is likely that most non-professional MHCII-expressing cells exhibit 
MHCII antigen presentation capacity to some degree, their efficiency depending on 
how well they execute the required steps of MHCII processing and presentation 
outlined above; the manner in which these APCs influence CD4+ T cell function is 
further influenced by the cohort of costimulatory molecules they express. Indeed, 
atypical MHCII+ cells have been shown to make substantial contributions to CD4+ T 
cell responses in a variety of immune settings, as detailed in the next section. 
 
 
1.7 Non-professional MHCII-expressing APCs 
Both at homeostasis and during disease states, there are various MHCII+ 
cells aside from DCs, macrophages, and B cells. Here I provide a few examples of 
such cell types, and I briefly discuss the mechanisms regulating their MHCII 
expression as well as their reported antigen presentation functions. 
The most extensively characterized MHCII+ non-professional cell is the 
thymic epithelial cell (TEC). TECs express MHCII at homeostasis. As expected, 
since they are nonhematopoietic cells, their transcription of MHCII is driven by the 
pIV isoform of CIITA [87]. However, departing from the paradigm discussed in 1.5, 
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their recruitment of CIITA pIV is IFNg-independent. The main function of TECs is to 
mediate selection of T cells in the thymus, and they directly contribute to CD4+ T cell 
development by presenting antigen via MHCII [88]. 
Another cell type more recently described to express MHCII are intestinal 
type 3 innate lymphoid cells (ILC3). ILC3s also express MHCII at homeostasis, but 
despite being HSC-derived immune cells, their expression of MHCII is driven by 
CIITA pIV. Similarly to TECs, they also do not require for IFNg for pIV induction [89]. 
MHCII antigen presentation by ILC3s to CD4+ T cells is critical for maintaining 
tolerance to the gut microbiota [89, 90]. 
Lymph node stromal cells (LNSC) also express MHCII at homeostasis. The 
expression of LNSC MHCII results from a combination of endogenous MHCII 
expression as well as the exogenous acquisition of MHCII proteins from 
hematopoietic cells [91-93]. In line with convention, LNSC intracellular production of 
MHCII is driven by CIITA pIV and requires IFNg [91]. MHCII antigen presentation by 
LNSCs to CD4+ T cells in secondary lymphoid organs contributes to the 
maintenance of peripheral tolerance and Treg induction [91-94].  
Although they are not professional APCs, TECs, ILC3s, and LNSCs are all 
cells with primary functions in the immune system. However, several other ostensibly 
“non-immune” cell types also express MHCII at homeostasis. Although the precise 
CIITA regulatory mechanisms have not been explored for most of these cells, at the 
time of writing, all of the cell types whose regulation has been studied have been 
found to require IFNg; thus, their homeostastic MHCII expression is driven by the low 
levels of IFNg present at steady-state. For example, intestinal epithelial cells (IEC) 
[95], which have been demonstrated to contribute to graft-versus-host disease and 
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to protect against colitis via MHCII antigen presentation to CD4+ T cells [96]. 
Endothelial cells (EC) are another such cell type (Figs 2.2, 2.4, 2.5), which have 
been demonstrated to present antigen via MHCII and to contribute to CD4+ T cell 
trafficking, effector CD4+ activation, as well as Treg induction [97-100]. 
The cell types discussed above are examples of some of the most well 
studied non-professional MHCII-expressing cells. However, other cell types have 
also been reported to express low levels of MHCII at homeostasis, and furthermore, 
in the setting of inflammation, essentially all nucleated cell types (except placental 
trophoblasts [101]) can be induced to produce MHCII in response to IFNg. An 
exhaustive summary of the antigen presenting functions of these cell types is 
beyond the scope of this dissertation, and has been reviewed thoroughly by 
Kambayashi and Laufer [102] and Duraes et al [103].    
Previous studies of bulk lung nonhematopoietic cells in particular have 
demonstrated that they also have the capacity to act as MHCII+ APCs. For example, 
in a lung transplant model, nonhematopoietic lung cells induce the formation of 
Tregs in vivo [97], and flu-infected nonhematopoietic lung cells can stimulate flu-
specific CD4+ T cells to produce IFNg in vitro [104]. Included in this 
nonhematopoietic MHCII+ cell population are lung type II alveolar cells (AT2s). The 
major focus of this dissertation is on the MHCII expression regulation and MHCII 
antigen processing and presentation capacity of AT2s. AT2s have been described to 
express MHCII at homeostasis in both mice [105-108] and humans [109, 110]. In the 
following sections, I discuss the role of AT2s in basic respiratory homeostasis, as 
well as their known functions in immune responses, in particular their interactions 
with CD4+ T cells via MHCII. 
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1.8 Functions of type II alveolar cells in lung physiology 
The respiratory system can be functionally divided into two parts: (1) the 
proximal portion responsible for conducting air, and (2) the distal portion responsible 
for gas exchange. The distal lung gas exchange parenchyma is composed of alveoli, 
blind-ended sacs separated by extremely thin interstitium containing pulmonary 
capillaries. The alveolar structures are composed of two epithelial cell types: AT2s 
and type I alveolar cells (AT1), as well as some stromal cells. AT1s are the very thin, 
flat cells that facilitate gas exchange across the blood/air interface and make up 
most of the surface area of the alveoli. AT2s on the other hand are much smaller, 
but are more numerous, cuboidal polarized cells that also play critical roles in basic 
respiratory homeostasis [111, 112]. 
One major function of AT2s is to produce surfactant. Surfactant is a 
phospholipid-protein mixture that is secreted into the alveolar spaces, where it 
reduces surface tension to prevent alveolar collapse. Defects in surfactant 
production are either incompatible with life or result in severe respiratory disease. 
Surfactant is composed of approximately 10% protein (including specific surfactant 
proteins SP-A, SP-B, SP-C, and SP-D), and ~90% lipids/phospholipids . While some 
other cell types can produce select surfactant proteins, AT2s are the only cells 
capable of producing all of the lipid and protein components of surfactant, and the 
only cell type that synthesizes mature SP-C protein [111-113]. 
AT2s possess a highly specialized network of subcellular compartments that 
are tailored to the synthesis, secretion, and recycling of surfactant. The surfactant 
proteins and lipids are produced in the ER, with SP-C and SP-B first synthesized as 
pro-proteins. SP-A and SP-D exit the ER via the Golgi and then are released via the 
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constitutive secretory pathway. In contrast, pro-SP-C and pro-SP-B, along with 
lipids, traffic from the Golgi to multi-vesicular bodies (MVB), then to a specialized 
lysosome-like compartment called the lamellar body (LB). Throughout this trafficking 
process, pro-SP-B and pro-SP-C are subject to a number of controlled proteolytic 
cleavage events carried out by processing enzymes that include cathepsins and 
other proteases. The LB contents are then released into the alveolar spaces via 
regulated exocytosis. Surfactant components can also be taken up from the alveolar 
spaces by AT2s via endocytosis, first into early endosomes. Components can either 
traffic to the lysosome for degradation, or back to the MVB where they may be either 
recycled to the LB, or at that point targeted to the lysosome [111, 114].  
Another major function of AT2s is to serve as stem cell-like progenitor cells in 
the distal lung. AT2s are capable of proliferation, self-renewal, and terminal 
differentiation, giving rise to both AT2 and AT1 daughter cells. This process operates 
at homeostasis, where cell turnover is relatively slow (on the order of weeks) [111]. 
Additionally, after lung injury, AT2s also contribute to the repopulation of the 
damaged alveolar epithelium [112, 115], in concert with other epithelial cell types 
[116]. 
Aside from these functions in respiratory biology and lung homeostasis, AT2s 
have also been described to have a number of immune functions. I will first introduce 
the immunologic environment of the lower respiratory tract in 1.9 and then discuss 




1.9 The lower respiratory tract immune system 
The proximal conducting airways are lined by mucosal tissue and thus 
maintain a rich mucosal immune system that is populated by numerous immune cell 
types and tertiary lymphoid structures. In contrast, the gas exchange alveolated lung 
parenchyma is comprised of non-mucosal thin epithelium that represents a distinct 
immunologic context [117]. As this latter portion is where AT2s reside, I limit my 
discussion here to the immune environment of the alveolar portion of the lower 
respiratory tract. 
The alveolar spaces contain a number of immune cells at homeostasis. The 
most abundant are alveolar macrophages, which reside inside the alveolar spaces 
[117]. There are also two main types of conventional DCs: CD103+ DCs, which lie 
closer to the epithelial layer and extend processes into the alveolar spaces, and 
CD11b+ DCs that reside more squarely in the interstitium [6]. The interstitium 
between alveolar spaces also contains various other myeloid cells, including 
interstitial macrophages, monocyte-derived DCs, and plasmacytoid DCs, as well as 
T and B cells, and mast cells, NK and innate lymphoid cells, and others [6, 117].  
The extensive pulmonary vasculature embedded in the lung parenchyma also 
contains a variety of immune cells, including large numbers of T cells [117]. During 
inflammation there is an additional influx of cell types, depending on the type of 
immune response, including neutrophils, eosinophils, additional T cells, and 
inflammatory monocytes, among others [6, 117]. 
As one area of emphasis of this dissertation is the primary T cell response to 
respiratory viral pathogens, I will also outline briefly the current understanding of the 
key steps in the antiviral adaptive immune response in the lung, using the response 
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to influenza virus in mice as an example. The first cells to respond to influenza virus 
are epithelial cells, which are the major target of infection, as well as the highly 
phagocytic alveolar macrophages surveying the alveolar spaces [6]. Activation of 
innate sensors within these cells leads to the production of type I/III interferons and 
other inflammatory cytokines and chemokines that have direct antiviral effects and 
also serve to recruit and activate other immune cells [118]. This process, along with 
direct pathogen sensing, triggers antigen uptake and maturation of DCs, which then 
exit the lung to enter the draining lymph nodes where they interact with naïve T cells 
by presenting viral antigens via MHCI and MHCII. Although both lung DC types can 
prime naïve CD4+ and CD8+ T cells, CD103+ DCs are thought to be the main 
contributors to CD8+ T cell priming, arriving in large numbers to the draining lymph 
node earlier during the course of infection (days 2-4). CD11b+ DCs are thought to be 
more important for cytokine and chemokine production in the lung and for the 
expansion of the effector T cell pool, and they peak in the lymph nodes later during 
infection (days 5-7) [6]. A subset of activated CD4+ T cells remains in the lymph node 
as Tfh cells that interact with B cells in germinal centers, leading to the differentiation 
of flu-specific memory B cells as well as plasma cells that produce high affinity 
neutralizing antibodies [6]. Antigen-specific effector Th1 CD4+ T cells and CD8+ T 
cells traffic back to the lung, where they interact with both directly infected and 
antigen-bearing APCs via recognition of cognate peptide/MHC complexes. These 
antigen-specific T cell/APC interactions in situ are critical for direct effector T cell 
functions that facilitate viral elimination, such as direct cytolysis of infected cells by 
CD8s, and by CD4s to a small extent [119], as well as for Th1 CD4+ and CD8+ 
production of antiviral cytokines such as TNFa and IFNg. In general, these direct 
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TCR-peptide/MHC interactions in the lung tissue, along with concomitant 
costimulatory or inhibitory signals and particular cytokines, serve to support and 
regulate the viability, proliferation, and function of effector T cells locally [6, 120-125]. 
Once the virus is cleared, the responding effector T cell populations contract, and a 
memory T cell pool persists both centrally and in the lung tissue. A failure to properly 
regulate these T cell responses, in terms of magnitude, duration, or phenotype, can 
result in lung immunopathology [126].   
 
 
1.10 Type II alveolar cells in lung innate and adaptive immune responses 
Aside from their roles in respiratory function and lung regeneration, AT2s 
have also been described to play a number of key immune functions at homeostasis 
and during infection. 
AT2s contribute to constitutive immune defenses in the lung. Surfactant 
proteins SP-A and SP-D produced by AT2s can act as opsonins, binding to the 
surface of various pathogens and accelerating their uptake by alveolar macrophages 
[127]. AT2s also secrete complement components as well as lysozyme, which help 
facilitate microbial clearance [128, 129]. AT2s also contribute to immune tolerance in 
the lung at homeostasis by providing negative regulatory signals to alveolar 
macrophages via the CD200/CD200R and TGFb axes [6, 117, 118]. 
During infection, AT2s express a number of pattern recognition receptors, 
such as TLRs as well as the nucleic acid sensors MDA-5 and RIG-I, which allow 
them to detect pathogens and initiate further immune responses [130, 131]. AT2s 
can also secrete a number of different cytokines and chemokines, such as IL-6, IL-8, 
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IL-1b, GM-CSF, IL-4, IFN-g, type I/III IFNs, and others, which can serve to recruit 
and promote the survival and function of inflammatory cells [111, 130, 132-136]. 
More than 30 years ago, it was first described that AT2s express MHCII at 
homeostasis in rodents and humans [137, 138], and a number of subsequent studies 
have confirmed these expression findings [105-110, 139-141]. However, there have 
been relatively few studies directly addressing the contribution of AT2s to adaptive 
immune responses via MHCII, and those that have been performed report somewhat 
conflicting functions.  Cunningham and colleagues first explored the antigen 
presenting capabilities of AT2s. They found that primary human AT2s were unable to 
stimulate allogeneic CD4+ T cells to proliferate in a 5 day in vitro co-culture; however, 
proliferation could be induced by adding high concentrations of anti-CD28 antibody 
(≥10µg/mL) to the culture [110]. Debbabi et al. subsequently demonstrated that 
primary murine AT2s pre-incubated with M. tuberculosis (Mtb) sonicate could 
stimulate polyclonal Mtb-experienced CD4+ T cells to produce IFNg in a 48 hour in 
vitro co-culture, without the need for exogenous co-stimulation. They also 
demonstrated that in the presence of Mtb protein antigen, AT2s could stimulate the 
Mtb-specific CD4+ T cell hybridomas to produce IL-2 [106]. Conversely, Lo and 
colleagues demonstrated that ovalbumin protein (Ova) treated AT2s failed to 
stimulate Ova-specific CD4+ T cell hybridomas as well as primary Ova-specific CD4+ 
T cells (OT-II) to produce IL-2 or proliferate, even in the presence of synthetic Ova 
peptides or when the AT2s had been pre-treated in vivo with IFNg. They further 
demonstrated that OT-II cells pre-incubated with AT2s in vitro become tolerized, or 
are suppressed in an antigen specific manner from subsequent DC-mediated 
activation [108]. In contrast, using the same Ova system, Gereke et al. demonstrated 
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that primary mouse AT2s treated with Ova protein in vitro or in vivo were capable of 
stimulating proliferation of naïve OT-IIs in in vitro co-culture. They also showed that 
primary AT2s expressing HA protein endogenously under the SP-C promoter 
(derived from SPC-HA mice) could stimulate naïve HA-specific CD4+ T cells (derived 
from TCR-HA mice) to proliferate in vitro. They further proposed that the effect of 
AT2s on CD4+ T cells is context dependent, as AT2s derived from TCR-HA x SPC-
HA mice, which experience severe autoimmune lung disease, instead induced TCR-
HA T cells to become Tregs in vitro rather than to proliferate. They also suggest that 
AT2s mediate these dynamic interactions with naïve CD4+ T cells in vivo as well, by 
demonstrating TCR-HA proliferation in the lungs of SPC-HA CD11c-DTR mice and 
of SPC-HA mice treated with the lymph node egress inhibitor, FTY720; however, 
whether their experimental interventions reflect endogenous MHCII antigen 
presentation by AT2s or MHCII presentation by residual CD11c+ or other non-
CD11c+ hematopoietic lung-resident APCs that acquire exogenous HA from the 
AT2s is unclear [107].   
In summary, these prior studies exhibit substantial variation in their findings of 
AT2 MHCII antigen presentation capacity and its functional influence on the CD4+ T 
cell response. Furthermore, only Gereke and colleagues [107] attempted to explore 
the in vivo impact of AT2 MHCII presentation, and they did so in the context of a 
model system that forces high and artificial protein expression in the AT2s, and 
where it is unclear whether the in vivo MHCII presentation measured was mediated 
by AT2s or by other lung APCs. Importantly, no prior studies have investigated the 
contribution of AT2 MHCII to host defense in vivo, nor have any explored 
mechanisms regulating homeostatic AT2 MHCII expression. In this dissertation, I 
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aim to shed light on these previously unexplored areas and to clarify the 
discrepancies previously reported in AT2 MHCII function. 
 
 
1.11 Goals for the thesis  
The overarching goal of this dissertation is to better understand the function 
of MHCII on AT2s. Specifically, I aim to elucidate (1) how MHCII expression by AT2s 
is regulated, (2) the contribution of AT2 MHCII to lung antiviral host responses, and 
(3) the MHCII antigen presentation capabilities of AT2s. A driving purpose for this 
work is the need to better understand how immune responses are carefully 
orchestrated in the lung parenchyma to facilitate rapid pathogen clearance while 
preventing collateral immunopathology that would damage the vital gas-exchange 
surface; I seek to understand if and how AT2s contribute to this regulation.  
In chapter 2, I investigate the MHCII+ APC characteristics of AT2s. First, I 
explore the mechanisms by which AT2s express MHCII protein as well as the 
transcriptional mediators and cytokine signals required for AT2 MHCII expression. I 
also assess the capacity of AT2s to mediate antigen uptake and proteolysis, as well 
as their expression of conventional MHCII trafficking and peptide loading 
chaperones. 
In chapter 3, I investigate the function of AT2 MHCII in vivo. Using a 
conditional mouse model, I selectively eliminate MHCII just on AT2s. I assess the 
impact of the loss of AT2 MHCII on disease and immune dysfunction at homeostasis 
as well as during lower respiratory tract viral infection. 
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In chapter 4, I explore the MHCII antigen presentation capabilities of AT2s. I 
assess the capacity of AT2s to process and present antigens via MHCII both in vitro 
and in vivo, using viral and model protein systems to look on an aggregate and 
epitope-specific basis. 
In chapter 5, I discuss the implications of our findings and consider future 
avenues of investigation.   













CHAPTER 2:  
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CD4+ T cell responses are initiated by T cell receptor (TCR) recognition of 
cognate major histocompatibility complex II (MHCII)/peptide complexes on the surface 
of antigen presenting cells (APCs). By convention, constitutive MHCII expression is 
restricted to a few specialized types of cells, including the “professional APCs” B cells, 
dendritic cells (DCs), and macrophages, as well as thymic epithelial cells (TECs) [52]. 
In contrast, all other cell types are thought to produce MHCII only in the setting of 
inflammation, specifically in response to the cytokine interferon-g (IFNg) [58].  
However, more recently, an increasing number of other cell types have been shown 
to express MHCII at homeostasis, violating this expression paradigm, as discussed in 
1.7. These include intestinal ILC3s [89, 90], which express MHCII independent of IFNg, 
as well as several nonhematopoietic cell types, such as lymph node stromal cells [91-
94], vascular endothelial cells [98-100], and intestinal epithelial cells [95, 96, 142], 
whose MHCII production is driven by the basal IFNg present at steady state. 
Type II alveolar cells (AT2s) are an additional nonhematopoietic cell type that 
have been reported to express MHCII at homeostasis in both mice [105-108] and 
humans [109, 110]. As described in 1.8, AT2s are epithelial cells present in the lung 
parenchyma, and their main physiologic functions are to produce surfactant and to 
serve as stem-like cells in the distal lung [112, 115, 143, 144]. Their constitutive MHCII 
expression suggests that they may participate in lung adaptive immune responses as 
well.  Previous studies of AT2 MHCII function have varied widely in their findings [106-
108, 110], and as such, the capacity of AT2s to act as MHCII+ APCs remains unclear. 
Furthermore, no prior studies have attempted to understand the mechanisms driving 
this unusual homeostatic MHCII expression by AT2s. Thus, here I report on the 
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mechanisms regulating AT2 MHCII expression at homeostasis, and I begin to assess 

















AT2s express MHCII protein at homeostasis to uniformly high levels 
To verify prior reports of homeostatic AT2 MHCII expression, we assessed 
MHCII on both mouse and human AT2s by flow cytometry. Mouse AT2s were 
identified as CD45-CD31-EpCAMint cells (Fig 6.1) [105], while human AT2s were 
identified by expression of the cell surface marker HT2-280 (Fig 6.2) [145]. Consistent 
with prior studies, we found that naïve wild-type C57Bl/6 (B6) AT2s uniformly express 
MHCII (Fig 2.1a). Similarly, healthy human AT2s express the human MHCII protein 
HLA-DR (Fig 2.1b). 
 
We next compared MHCII levels on AT2s to other well studied MHCII-
expressing lung cells in naïve mice. AT2s express MHCII at a magnitude similar to 
that of lung professional APCs, dendritic cells (DCs) and B cells, and higher than 
alveolar macrophages (Fig 2.2a). Besides AT2s, vascular endothelial cells (ECs) are 
another nonhematopoietic cell type in the lung that express MHCII at homeostasis 
[97]. Compared to ECs, AT2 MHCII expression is higher and more homogeneous (Fig 
2.2b). 
 
Figure 2.1: Mouse and human AT2s express MHCII at homeostasis. a, MHCII protein 
expression by AT2s from naïve C57Bl/6 (B6) wild-type (WT) and MHCII-/- mice measured by flow 
cytometry; represents n>10 mice per strain total from >5 independent experiments. b, MHCII 
(HLA-DR) protein expression by AT2s and distal lung cells from a healthy human donor measured 




MHCII protein may be synthesized intracellularly or extrinsically acquired [59] 
from conventional APCs. We examined the source of AT2 MHCII by qPCR and by 
creating CD45.1 MHCII+/+ (B6CD45.1) and CD45.2 MHCII-/- B6 (MHCII-/-) bone marrow 
chimeric mice. AT2s express transcript for both the a and b chains of the MHCII allele 
in B6 mice, I-Ab (Fig 2.3a), and AT2s retained MHCII protein expression to high levels 
in MHCII-/- à B6CD45.1 mice (Fig 2.3b). Thus, AT2s synthesize their own MHCII and do 
not depend on acquisition of MHCII protein from hematopoietic APCs.  
 
Figure 2.2: AT2s express high levels of MHCII similar to professional APCs. a,b, MHCII 
protein expression by AT2s, CD103+ dendritic cells (CD103+ DC), B cells, alveolar macrophages 
(Alv mac), and endothelial cells (EC), from naïve B6 WT mouse lungs measured by flow cytometry; 
represents n>10 mice per strain total from >5 independent experiments. 
 
Figure 2.3: AT2s synthesize their own MHCII transcript and protein. a, I-Ab a (H2-Aa) and b 
(H2-Ab1) chain transcript abundance relative to housekeeping gene Hprt1, in AT2s and lung 
dendritic cells (DC) sorted from naïve B6 WT mice, and a B6 fibroblast cell line (B6 Fib), measured 
by quantitative RT-PCR; n=3 mice for AT2s, n=2 mice for DCs, bars represent mean plus standard 
error of the mean (SEM), 1 representative experiment shown of 2 similar independent 
experiments. b, MHCII protein expression by AT2s in MHCII-/- and CD45.1 B6 (B6CD45.1) bone 
marrow chimeric mice, measured 8 weeks post-transplantation with transfers as indicated; 
histograms represent n=2-4 mice per group in 1 experiment.  
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In sum, AT2s represent a unique population of nonhematopoietic lung cells 
that produce MHCII protein at homeostasis uniformly to high levels, similar to that of 
professional APCs. 
 
AT2 MHCII expression is regulated in an unconventional, IFNg-independent manner 
The class II transactivator (CIITA) is the master transcription factor that drives 
MHCII expression [58]. To determine whether AT2 MHCII expression is dependent on 
CIITA, we assessed MHCII in the lungs of Ciita-/- mice. Lack of CIITA results in the 
complete loss of MHCII expression on AT2s, as well as lung DCs and ECs (Fig 2.4). 
As discussed in 1.5, transcription of CIITA begins at three different promoter sites (pI, 
pIII, and pIV) depending on cell and context specific stimuli. Recruitment of pI occurs 
in DCs and macrophages, pIII in B cells and plasmacytoid DCs, and pIV in ILC3s and 
nonhematopoietic cells [58, 89]. To assess whether AT2 MHCII is dependent on pIV, 
we evaluated mice lacking just the pIV region within the CIITA locus [146]. AT2s from 
Ciita pIV-/- mice fail to express MHCII, as do ECs, while DCs retain MHCII expression 
as expected (Fig 2.4). 
 
Figure 2.4: AT2 MHCII expression is driven by CIITA pIV. MHCII protein expression by AT2s, 
CD103+ DCs, ECs from naïve B6 WT, MHCII-/-, Ciita-/-, and Ciita pIV-/- mouse lungs, measured by 
flow cytometry. For each strain, MHCII expression is displayed as a percentage reflecting the 
average median fluorescence intensity (MFI) of MHCII on each cell type relative to the average 
MHCII MFI on the same cell type in WT mice; n=2-4 mice per strain total from 1-2 independent 







































































The recruitment of pIV in all nonhematopoietic cells (except for thymic epithelial 
cells (TECs)) is thought to require induction by the cytokine IFNg [58]. We evaluated 
MHCII in mice deficient in IFNg, IFNgR, and the associated downstream pIV-binding 
transcription factor, STAT1. AT2s retain MHCII expression in Ifng-/-, Ifngr1-/-, and 
Stat1-/- mice in a manner similar to DCs and in contrast to ECs, whose MHCII 
expression is abrogated in the absence of IFNg signaling (Fig 2.5). AT2s, like DCs, 
exhibit a small reduction in MHCII expression in Stat1-/- mice, indicating that IFNg 
signaling may upregulate MHCII expression in AT2s, but it is not required for steady 
state expression. 
 
Besides IFNg, no other cytokine has been shown to be sufficient to induce 
MHCII expression in nonhematopoietic cells.  However, given the IFNg-independent 
expression of MHCII by AT2s, we also examined the requirement of a broad array of 
conventional innate and adaptive immune mediators, by assessing Ifnar1-/-, Ifnar1-/- x 
Ifngr1-/-, Myd88-/-, Stat6-/-, and germ-free mice. AT2s express MHCII at wild-type levels 
 
Figure 2.5: AT2 MHCII expression does not require canonical IFNg inflammation. MHCII 
protein expression by AT2s, CD103+ DCs, ECs from naïve B6 WT, MHCII-/-, Ifng-/-, Ifngr1-/-, and 
Stat1-/- mouse lungs, measured by flow cytometry. For each strain, MHCII expression is displayed 
as a percentage reflecting the average median fluorescence intensity (MFI) of MHCII on each cell 
type relative to the average MHCII MFI on the same cell type in WT mice; n=2-4 mice per strain 










































































in all cases (Fig 2.6), indicating that they also do not require a wide spectrum of other, 
non-IFNg inflammatory signals for MHCII expression, including type I IFNs, TLR 
ligands, IL-1, IL-18, IL-33, Th2 cytokines, and the microbiota. 
 
Altogether, these data demonstrate that AT2 homeostatic MHCII expression is 
CIITA pIV-dependent, but IFNg-independent. This same transcriptional configuration 
has been reported for only two other cell types: TECs[87], which are present in a 
primary immune organ, and ILC3s [89], which are immune cells. To our knowledge it 
has never been described for a cell outside of the immune system. 
 
 
AT2s possess classical APC characteristics and MHCII antigen processing and 
presentation machinery 
Although the spectrum of “required” machinery for MHCII antigen processing 
and presentation can vary widely depending on the particular epitope generated and 
 
Figure 2.6: AT2s express MHCII independent of a variety of broad innate and adaptive 
inflammatory mediators. MHCII protein expression by AT2s, from naïve B6 WT, MHCII-/- Stat6-
/-, Ifnar1-/-, Ifnar1-/-Ifngr1-/-, Myd88-/-, and germ-free mice, measured by ex vivo flow cytometry 
analysis and displayed as MFI of AT2s from each strain relative to WT AT2s; n=2-3 mice per strain 













































APC involved, as discussed in chapter 1, we nonetheless sought to understand to 
what extent AT2s possess general characteristics that would contribute to their 
capacity to act as MHCII+ APCs. 
We first examined whether AT2s possess mediators of classical MHCII 
presentation. By convention, this pathway begins with extracellular antigen acquisition 
followed by proteolysis in the endocytic compartment [17, 18, 147]. To assess these 
steps, we evaluated the capacity of AT2s to catabolize DQ-Ova, a self-quenched 
conjugate of ovalbumin protein that fluoresces after receptor-mediated endocytosis 
and proteolytic digestion. AT2s exhibited a temperature-dependent increase in 
fluorescence when incubated with DQ-Ova, less so than DCs but similarly to B cells, 
indicating that they are capable of active antigen uptake and degradation (Fig 2.7).  
Optimal MHCII presentation also requires appropriate stabilization and 
trafficking of MHCII. Classically, this is facilitated by the chaperone protein invariant 
chain [17, 18, 147]. We evaluated invariant chain expression by flow cytometry and, 
consistent with prior reports [105, 148], found that AT2s express intracellular invariant 
chain in both mice (Fig 2.8a) and humans (Fig 2.8b). 
 
Figure 2.7: AT2s are capable of extracellular antigen uptake and degradation. Fluorescence 
of AT2s, B cells, and DCs sorted from naïve B6 WT lungs then incubated with DQ-ovalbumin (DQ-
ova) or media at the temperatures indicated, measured by flow cytometry; histograms represent 
n=2 mice total from 2 independent experiments. 
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Classical MHCII processing also depends on the protein H2M, which facilitates 
removal of the invariant chain peptide remnant CLIP from the MHCII peptide-binding 
groove in the late endosome [17, 18, 147]. We evaluated H2M expression by qPCR 
and flow cytometry. In mice, H2M is a heterodimeric protein composed of one a chain 
pairing with one of two b chains, b1 or b2 [30]; H2Mab1 and H2Mab2 are thought to 
function similarly [149, 150]. AT2s expressed detectable levels of transcripts encoding 
the a and b chains of H2M (Fig 2.9a), using b primers that capture both b1 and b2. 
However, by flow cytometry AT2s did not express H2Mab2 protein (Fig 2.9b). Thus, 
the predominant form of H2M in naïve mouse AT2s is H2Mab1, consistent with 
publicly availably RNA-seq data (Fig 2.10) deposited on the LungMAP Consortium 
(U01HL122642). We also evaluated H2M function by flow cytometric detection of the 
CLIP/MHCII complex CLIP/I-Ab in B6 mice. If H2M is functionally present, then the 
 
Figure 2.8: AT2s express invariant chain protein. a, Intracellular invariant chain protein 
expression by AT2s, lung CD103+ DCs, and splenic B cells from B6 WT or invariant chain deficient 
(Cd74-/-) mice measured ex vivo by flow cytometry; histograms represent n=3-9 mice per strain 
from 3 independent experiments. b, Intracellular invariant protein expression by AT2s and distal 
lung cells from a healthy human donor measured by flow cytometry; represents n=1 donor, and 
gate was drawn based on fluorescence minus one (FMO) controls. 
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number of CLIP/I-Ab complexes will be low, as CLIP peptide will be edited out.  AT2s 
from wild-type mice have low expression of CLIP/I-Ab complexes, similar to 
hematopoietic MHCII+ lung cells, and in contrast to both cell types from H2M-deficient 
mice that have high levels of CLIP/I-Ab (Fig 2.9c). We also assessed the expression 
of the human H2M-equivalent, HLA-DM, in human AT2s, by flow cytometry. As in 
mice, healthy human AT2s expressed HLA-DM (Fig 2.9d).  
 
Figure 2.9: AT2s express functional H2M protein. a, H2Ma and H2M-b chain transcript 
abundance relative to housekeeping gene Hprt1, in AT2s and DCs sorted from naïve B6 WT 
mouse lungs, and a B6 fibroblast cell line (B6 Fib), measured by quantitative RT-PCR; n=3 mice 
for AT2s, n=2 mice for DCs, data shown are mean plus SEM, 1 representative experiment shown 
of 2 similar independent experiments. b, Intracellular H2Mab2 protein expression by AT2s and 
lung B cells from B6 WT or H2Ma deficient (H2-DMa-/-) mice measured ex vivo by flow cytometry 
with frequency of H2Mab2+ cells shown; plots represent n>10 mice per strain total from >5 
independent experiments. Gates were drawn separately for AT2s and B cells based on their H2Ma 
deficient cell counterparts. c, Surface MHCII and CLIP/I-Ab H2Mab2 protein expression by AT2s 
and bulk CD45+MHCII+ cells from B6 WT or H2Ma deficient mice measured ex vivo by flow 
cytometry with frequency of MHCII+CLIP/I-Ab+ cells shown; plots represent n>6 mice per strain 
total from >3 independent experiments. d, Intracellular HLA-DM protein expression by AT2s and 
distal lung cells from a healthy human donor measured by flow cytometry; represents n=1 donor, 
and gate was drawn based on fluorescence minus one (FMO) controls. 
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Besides extracellular antigens, MHCII also presents peptides derived from 
intracellular proteins [35, 47, 49]. For example, in influenza (flu) virus infections in B6 
mice, endogenous MHCII presentation of peptides from viral proteins synthesized 
within infected cells, instead of engulfed extracellular viral material, drives the majority 
of the antiviral CD4+ T cell response [46]. Endogenous MHCII presentation involves a 
heterogenous network of machinery that are less well characterized compared to the 
classical pathway, precluding an exhaustive study of specific mediators here. 
However, one prerequisite for endogenous processing is expression of intracellular 
antigen by the APC. We assessed whether AT2s produce viral proteins intracellularly 
after exposure to live influenza virus and found that AT2s expressed both 
hemagglutinin (HA) as well as nucleoprotein (NP) to high levels (Figs 4.2, 4.4). This 
suggests that AT2s possess abundant substrate material for endogenous processing 
during flu infections, and this presumably extends to other respiratory viral infections 
for which they are also main targets. 
 
Figure 2.10: AT2s express exclusively H2Mb1 transcripts, not H2Mb2, at homeostasis. 
H2Mb1 and H2Mb2 chain transcript abundance measured by bulk RNA-seq, normalized by 
RPKM, in AT2s from naïve 4 week old B6 mice. The results shown here are in whole based upon 
data deposited on the LungMAP Consortium by J. Whitsett and Y. Xu. They were downloaded 
from (www.lungmap.net), on Nov 18, 2018. The LungMAP consortium and the LungMAP Data 















Beyond peptide/MHCII complex formation, another component of APC function 
is the provision of costimulation. In general, priming of naïve T cells requires APC 
expression of the proteins CD80 or CD86, while the reactivation of effector T cells is 
less costimulation-dependent and may be influenced by a wider spectrum of 
costimulatory molecules [7, 151]. Prior studies indicate that naïve AT2s do not express 
CD80 or CD86, but that they express the noncanonical costimulatory molecule ICAM-
1 [106-108]. We also assessed AT2s for CD80, CD86, and ICAM-1 expression and 
found that AT2s expressed ICAM-1, but not CD80 or CD86, both at homeostasis and 
after influenza infection (Fig 2.11). 
Taken together, these data indicate that AT2s possess the requisite 
characteristics and intracellular machinery to endow them with MHCII antigen 
presentation capacity; in combination with the expression of ICAM-1 but not 
CD80/CD86, this would predict that AT2s have the ability to act as APCs, activating 




Figure 2.11: AT2s express noncanonical costimulatory molecule ICAM-1, but not CD80 or 
CD86. a, Surface expression of CD80 (left) and CD86 (right) by AT2s from naïve mice or mice 5 
days post influenza virus infection, and B6 WT BMDCs cultured in vitro. b, Surface expression of 
ICAM-1 by AT2s from naïve mice or mice 5 days post influenza virus infection, and B6 WT 
splenocytes from naïve mice. Histograms represent n=2 mice (naïve) or n=6 mice (flu infected) in 




Here we establish that AT2 cells stand alone in a new category of MHCII-
expressing cells, as non-immune cells that nonetheless constitutively express MHCII 
in an IFNg-independent manner. We also demonstrate that AT2s express 
conventional MHCII-associated antigen processing machinery and APC qualities 
that should equip them with the capacity to present antigen to CD4+ T cells.  
We confirm prior reports of homeostatic MHCII expression by AT2s but also 
provide new insight into the magnitude of AT2 MHCII expression. We demonstrate 
that AT2s uniformly express high levels of MHCII, making them unusual in 
comparison to other nonhematopoietic cell types that express MHCII at 
homeostasis, which typically do so to lower levels; for example, lung endothelial cells 
(Fig 2.2b) and lymph node stromal cells [93] exhibit low to intermediate levels and 
much less homogeneous expression of MHCII. As AT2s comprise about 15% of lung 
parenchymal cells [111], this makes them one of the most abundant high-MHCII-
expressing cells in the lung, even including the professional APCs. 
Prior to our work, no previous studies of AT2s had investigated the 
mechanisms driving their homeostatic MHCII expression. Based on the accepted 
paradigm for MHCII expression in nonhematopoietic cells, we hypothesized that AT2 
MHCII would be driven by CIITA pIV in response to IFNg. Intestinal epithelial cells, 
which, like AT2s, are epithelial cells at a barrier site continuously exposed to antigen, 
express MHCII at homeostasis driven by the low levels of basal IFNg that are 
present at steady state [95]; we presumed that AT2s would follow this same pattern. 
However, we demonstrated that AT2 MHCII, while dependent on CIITA pIV, is 
independent of IFNg and a number of other mediators that span multiple broad arms 
 40 
of the immune system. This indicates that CIITA pIV recruitment in AT2s follows a 
novel transcriptional induction mechanism that departs from the conventional model 
of CIITA regulation for non-immune cells. Furthermore, it suggests that AT2 MHCII is 
not driven by an inflammatory stimulus, but rather depends on other environmental 
cues or is an intrinsic part of the AT2 identity. Future work will aim to identify the 
general upstream signals and transcription factors that induce CIITA pIV and 
subsequent MHCII in AT2s, as detailed in chapter 5. Regardless of the specific 
mechanisms driving AT2 MHCII, constitutive expression to such high levels suggests 
that AT2 MHCII plays an important functional role in the lung.   
We demonstrated that AT2s are capable of acquiring exogenous and 
endogenous antigens and that they express conventional MHCII processing and 
presentation chaperones. Although there is no one set of intracellular mediators that 
is required for all MHCII presentation, the fact that AT2s possess these 
characteristics suggests that they have the capacity to be potent MHCII+ APCs.  As 
AT2s lack CD80/CD86 expression, this suggests that AT2s play a role in modulating 
the function of lung-infiltrating effector CD4+ T cells and/or in tolerizing naïve CD4+ T 
cells that migrate through the lungs [152], rather than mediating priming of naïve 
CD4+ T cells.   
We observed that AT2s express only the H2Mab1 isoform of H2M. We were 
intrigued by this differential expression of H2Mab1 and H2Mab2, since by 
convention they should be co-regulated under the control of CIITA. Per publicly 
available RNA-seq data deposited in the Immunological Genome Project [153], 
conventional APC populations also exhibit differential expression of H2Mab1 and 
H2Mab2, and the preferred isoform differs depending on cell type (Fig 2.12). B cells 
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appear to favor H2Mab2, DCs express both H2Mab1 and H2Mab2 to approximately 
equal levels, while macrophages are more variable depending on the tissue of origin 
but seem to favor H2Mab1 like AT2s. Given that both of these genes should 
theoretically be driven by the same transcription factor, this discordant expression 
suggests that there are cell-type specific mechanisms that further control 
transcription of each H2Mb gene. The functional significance of this regulation is 
unclear, as H2Mab1 and H2Mab2 have been shown to function similarly [149, 150], 
although admittedly no prior studies have addressed this very extensively. 
Furthermore, as the duplication of H2Mb seems to be unique to mice, it is unclear 
what relevance this differential expression has to humans; humans have only one 
gene for H2Mb, although it is polymorphic within the population as a whole [154, 
155]. 
Overall, AT2s constitutively express high levels of MHCII and possess 
promising MHCII+ APC characteristics. In the next chapter, we will directly examine 






Figure 2.12: APCs differentially express H2Mb1 and H2Mb2. a-c, H2Mb1 and H2Mb2 chain 
transcript abundance detected by bulk RNA-seq, normalized by DESeq2, of the splenic B cell 
subsets (a), splenic DC subsets (b), and macrophage populations (c) indicated, in naïve 6 week 











































CHAPTER 3:  
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In chapter 2 we demonstrated that AT2s possess robust APC characteristics, 
including constitutive and high MHCII expression. In this chapter, we examine how 
these features may translate into their in vivo function.  
In general, T cell responses are initiated and largely shaped by the priming of 
naïve T cells and their subsequent proliferation in a draining lymph node. However, 
effector T cells that then circulate back to the site of infection can also be further 
regulated by cognate peptide/MHC-expressing cells in the tissue. For example, in 
the lung during viral infections in particular, this has been demonstrated for both 
CD8+ and CD4+ T cell function and proliferation [120, 122-125]. Furthermore, fine 
tuning of CD4+ T cell responses, during either the priming or effector phase, also 
occurs in a number of other tissues and can be mediated by a variety of 
unconventional MHCII+ cells [102, 103]. For example, ILC3s have been 
demonstrated to induce deletion of commensal-specific CD4+ T cells via MHCII 
presentation in the intestine, which is critical to prevent gut immunopathology [89, 
90]. Intestinal epithelial cells have also been shown to regulate gut CD4+ T cells 
differentially depending on the disease setting; they contribute to worst graft-versus-
host disease pathogenesis by priming CD4+ T cells, but also regulate the Th1/Treg 
balance in the gut to prevent colitis [95, 96]. Furthermore, MHCII presentation by 
vascular endothelial cells has been demonstrated to modulate effector CD4+ T cell 
functions and trafficking [98, 99], while lymph node stromal cell MHCII presentation 
is important for the maintenance of peripheral CD4+ T cell tolerance [92, 94].  
Regulation of CD4+ T cell function in the periphery by these MHCII+ APCs 
primarily occurs via TCR binding to cognate peptide/MHCII complexes along with 
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accompanying activating or inhibitory receptor/ligand interactions, which serves to 
either amplify T cell activation or suppress T cell function. However, aside from 
antigen presentation, MHCII can also serve another role in regulating effector T cell 
function. MHCII is one of the major ligands for the inhibitory receptor LAG3, which is 
expressed on activated T cells. LAG3 binds directly to surface MHCII and this 
ligation results in suppression of T cell proliferation and effector function. MHCII 
binding to LAG3 restrains both CD4+ and CD8+ T cell responses in a number of 
disease settings, including viral infection, autoimmunity, and cancer [156].  
Only one prior study has assessed the in vivo function of MHCII on AT2s and 
how this might regulate T cell responses in the lung [107]. In this study, AT2s were 
reported to be capable of activating naïve CD4+ T cells in the healthy mouse lung 
and of inducing CD4+ Treg formation in the setting of lung inflammation. However, 
how well this experimental system, which relied on forced expression of a model 
protein to very high levels in AT2s and used responding TCR transgenic CD4+ T 
cells, represents a physiologic setting is unclear. Furthermore, while AT2s expressed 
the protein from which the MHCII-restricted epitope of interest was derived, it is 
unclear whether they were interacting directly with CD4+ T cells via MHCII or were 
simply releasing antigen that was then acquired and presented by professional 
APCs. Thus, the in vivo contribution of AT2 MHCII is still largely unknown, and in 
particular, its contribution to lung homeostasis and to lung host responses has never 
been explored to our knowledge. Thus, here we examine the function of AT2 MHCII 





A mouse model allows inducible and selective loss of MHCII on AT2 cells 
As AT2s express both MHCII and the conventional MHCII-associated APC 
machinery, we predicted that AT2 MHCII presentation would contribute to immune 
responses in vivo. To test this, we generated mice with an AT2-specific deletion of 
MHCII by breeding mice to have both (1) a tamoxifen-inducible Cre enzyme controlled 
by the AT2-specific surfactant protein C (SPC) promoter [157] and (2) LoxP sites 
flanking exon 1 of the I-Ab b chain on both alleles [158] (SPC-Cre-ERT2+/- × H2-Ab1fl/fl; 
aka “SPCDAb1”). Upon tamoxifen administration, SPCDAb1 mice exhibit uniform deletion 
 
Figure 3.1: SPCDAb1 mice demonstrate specific deletion of MHCII on AT2s. a, MHCII 
expression by AT2s from naïve SPC-Cre-ERT2+/- (SPCCre), H2-Ab1fl/fl (Ab1fl/fl), and SPC-Cre-
ERT2+/- × H2-Ab1fl/fl (SPCDAb1), lungs measured by flow cytometry; histograms represent n>50 
mice per strain total from >10 independent experiments. b, Immunofluorescence detection of 
MHCII, SPC, and E-Cadherin in Ab1fl/fl, SPCDAb1, and MHCII-/- lungs; scale bar depicts 20 µm and 
images represent n=1-2 mice per strain. c, Percent of each cell type expressing MHCII protein for 
lung AT2s, B cells, alveolar macrophages, CD103+ DCs, and spleen B cells and CD8+ DCs, from 
naïve SPCCre, Ab1fl/fl, and SPCDAb1 mice, measured by ex vivo flow cytometry analysis; bars show 
n=4 mice per strain from 1 experiment, representative of 2 similar independent experiments for 
the Ab1fl/fl and SPCDAb1 strains (n=8 mice total per strain). 
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of MHCII from AT2s (Fig 3.1), in contrast to the parental strains whose AT2s retain 
MHCII: those expressing the Cre enzyme with a wild-type I-Ab locus  (SPC-Cre-
ERT2+/- only; aka “SPCCre”), as well as those with homozygous floxed I-Ab alleles but 
no Cre (H2-Ab1fl/fl only; aka “Ab1fl/fl”). 
To ensure that the deletion of MHCII in SPCDAb1 mice was restricted to AT2s, 
we compared MHCII on various other APCs in the lungs and spleens of all three 
strains. Similar frequencies of lung B cells, alveolar macrophages, lung CD103+ DCs, 
splenic B cells, and splenic CD8a+ DCs, expressed MHCII in all three strains, 
suggesting that the Cre-mediated deletion of MHCII was AT2-specific (Fig 3.1c). 
However, the overall magnitude of MHCII on certain APCs, such as B cells and 
CD103+ DCs, was lower in both the SPCDAb1 and Ab1fl/fl mice compared to the SPCCre 
strain (Fig 3.2); this suggests that in mice of the H2-Ab1fl/fl genetic background, the I-
Ab targeting construct diminishes MHCII expression in some cell types, independent 
of Cre expression. Based on these data, we considered the Ab1fl/fl mice the most 
appropriate comparators for the SPCDAb1 mice, so these two strains were paired for 
our in vivo studies. 
 
Figure 3.2: Mice of the Ab1fl/fl background demonstrate lower expression of MHCII in some 
professional APCs, independent of Cre. MFI of each cell type expressing MHCII protein for 
lung AT2s, B cells, alveolar macrophages, CD103+ DCs, and spleen B cells and CD8+ DCs, from 
naïve SPCCre, Ab1fl/fl, and SPCDAb1 mice, measured by ex vivo flow cytometry analysis; bars show 
n=4 mice per strain from 1 experiment, representative of 2 similar independent experiments for 
the Ab1fl/fl and SPCDAb1 strains (n=8 mice total per strain). 
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AT2 MHCII contributes to lung T cell homeostasis in aged mice 
We first assessed whether loss of MHCII on AT2s resulted in immune 
dysfunction at homeostasis. To this end, we examined lung immune cells and splenic 
T cells by flow cytometry in naïve 7-month-old and 14-month-old SPCDAb1 and Ab1fl/fl 
mice. 
At 14 months of age, the SPCDAb1 mice exhibited a number of differences from 
Ab1fl/fl mice in the lung T cell compartment. While the overall numbers of lung CD4+ 
and CD8+ T cells were similar between the strains, significantly lower proportions of 
CD4+ and CD8+ T cells were effector memory phenotype (CD44+ CD62L-), and higher 
proportions were naïve (CD44- CD62L+), in SPCDAb1 mice compared to Ab1fl/fl mice 
(Fig 3.3). Furthermore, significantly lower proportions of lung CD4+ and CD8+ T cells 
in SPCDAb1 mice expressed the inhibitory receptor PD1, which is a marker of T cell 
activation and/or exhaustion, and the proliferation marker Ki67 (Fig 3.3). As surface 
MHCII is the main ligand for the T cell inhibitory receptor LAG3, which is also an 
activation/exhaustion marker, we also evaluated LAG3-expressing T cells in the lungs 
of both strains; we found that  SPCDAb1 mice had reduced frequencies of LAG3+ CD4+, 
but not CD8+, T cells (Fig 3.3). We also examined lung Tregs and found that the 
frequency was significantly reduced in SPCDAb1mice compared to Ab1fl/fl mice (Fig 3.3).  
Frequencies of CD69+CD11a+ CD4+ and CD69+ CD8+ T cells in the lungs were also 
lower in SPCDAb1mice, although did not meet statistical significance for CD4+s, 
reflecting lower proportions of tissue resident-memory (Trm) [159] and/or recently 











Figure 3.3: 14-month-old SPCDAb1 mice demonstrate disrupted lung T cell homeostasis. a-
g, Ex vivo flow cytometry analysis of naïve 14 month old Ab1fl/fl and SPCDAb1 mice lung T cells. 
Absolute number of lung CD4+ and CD8+ T cells (a), and frequency of lung CD4+ and CD8+ T cells 
expressing CD44, CD62L (b), PD1 (c), Ki67 (d), LAG3 (e), Foxp3 (f), and CD69, CD11a (g), as 
indicated; n=10-11 mice per strain from 1 experiment. Data shown are mean plus SEM, analyzed 
by unpaired two-tailed Student’s t-test, Welch’s t-test, or Mann-Whitney test depending on the 





































































































































































In contrast to the lungs, the spleen T cell compartments were more comparable 
between 14-month-old SPCDAb1 and Ab1fl/fl mice, although they did demonstrate some 
of the same, but less pronounced, trends in T cell activation and memory marker 








Figure 3.4: 14-month-old SPCDAb1 mice demonstrate relatively normal T cell homeostasis in 
the spleen. a-f, Ex vivo flow cytometry analysis of naïve 14 month old Ab1fl/fl and SPCDAb1 mice 
spleens. Absolute number of splenic CD4+ and CD8+ T cells (a), and frequency of CD4+ and CD8+ 
T cells expressing CD44, CD62L (b), PD1 (c), Ki67 (d), LAG3 (e), and Foxp3 (f), as indicated; 
n=10-11 mice per strain from 1 experiment. Data shown are mean plus SEM, analyzed by 






































































































































Furthermore, there were no differences in the frequencies and numbers of 
other lung immune cells, including alveolar macrophages, neutrophils, NK cells, gdT 





Figure 3.5: 14-month-old SPCDAb1 mice exhibit normal numbers and frequencies of immune 
cells in the lung. a-e, Ex vivo flow cytometry analysis of naïve 14 month old Ab1fl/fl and SPCDAb1 
mice lungs. Frequency and numbers of alveolar macrophages (a), neutrophils (b), NK cells (c), gd 
T cells (d), and B cells (e), as indicated; n=10-11 mice per strain from 1 experiment. Data shown 
are mean plus SEM, analyzed by unpaired two-tailed Student’s t-test or Mann-Whitney test 





































































































































In contrast to the 14-month-old mice, naïve 7-month-old SPCDAb1 and Ab1fl/fl 
mice demonstrated no differences in numbers or frequencies of the same lung or 






Figure 3.6: 7-month-old SPCDAb1 mice demonstrate normal T cell homeostasis in the lung. 
a-g, Ex vivo flow cytometry analysis of naïve 7-month-old Ab1fl/fl and SPCDAb1 mice lung T cells. 
Absolute number of lung CD4+ and CD8+ T cells (a), and frequency of lung CD4+ and CD8+ T cells 
expressing CD44, CD62L (b), PD1 (c), Ki67 (d), LAG3 (e), Foxp3 (f), and CD69, CD11a (g), as 
indicated; n=4 mice per strain from 1 experiment. Data shown are mean plus SEM, analyzed by 
unpaired two-tailed Student’s t-test, Welch’s t-test, or Mann-Whitney test depending on the 


















































































































































































Figure 3.7: 7-month-old SPCDAb1 mice demonstrate normal T cell homeostasis in the spleen. 
a-f, Ex vivo flow cytometry analysis of naïve 7-month-old Ab1fl/fl and SPCDAb1 mice spleens. 
Absolute number of splenic CD4+ and CD8+ T cells (a), and frequency of CD4+ and CD8+ T cells 
expressing CD44, CD62L (b), PD1 (c), Ki67 (d), LAG3 (e), and Foxp3 (f), as indicated; n=4 mice 
per strain from 1 experiment. Data shown are mean plus SEM, analyzed by unpaired two-tailed 









































































































































Overall, these data suggest that at homeostasis, AT2 MHCII facilitates the 
development of various antigen-experienced lung CD4+ and CD8+ T cell populations, 
including regulatory T cells, as well as memory T cells and those expressing markers 
of activation and proliferation. The impact of AT2 MHCII on the T cell compartment is 
less pronounced in the spleen, it does not appear to impact non-T cell lung immune 
populations, and its contribution only becomes apparent with advanced mouse age. 
 
Figure 3.8: 7-month-old SPCDAb1 mice exhibit normal numbers and frequencies of immune 
cells in the lung. a-e, Ex vivo flow cytometry analysis of naïve 7-month-old Ab1fl/fl and SPCDAb1 
mice lungs. Frequency and numbers of alveolar macrophages (a), neutrophils (b), NK cells (c), gd 
T cells (d), and B cells (e), as indicated; n=4 mice per strain from 1 experiment. Data shown are 
mean plus SEM, analyzed by unpaired two-tailed Student’s t-test or Mann-Whitney test depending 


































































































































We next explored whether the loss of AT2 MHCII and its impact on lung T cells 
might result in lung disease at homeostasis. To do this, we compared hematoxylin and 
eosin (H&E) staining of naïve 9-month-old SPCDAb1 and Ab1fl/fl lungs. Both strains 
demonstrated normal, healthy lung architecture with minimal infiltrates (Fig 3.9), 
suggesting that loss of AT2 MHCII does not result in overt lung disease in these mice.  
 
 
Finally, we also investigated whether AT2 MHCII might play a non-immunologic 
role at homeostasis. Specifically, we asked whether AT2 MHCII is required for the two 
main physiologic functions of AT2s: lung regeneration and surfactant production. AT2s 
sorted from SPCDAb1 and Ab1fl/fl mice formed similar numbers of lung organoids in vitro 
(Fig 3.10). Furthermore, the SPCDAb1 mice did not experience any respiratory disease 
at homeostasis, clinically or histologically (Fig 3.9); significant lung disease would be 
expected if surfactant biosynthesis were disrupted. Together, this suggests that AT2 
MHCII is not required for either of these critical functions. 
 
 
Figure 3.9: 9-month-old SPCDAb1 mice demonstrate healthy lung histology with no 
inflammatory infiltrates. H&E staining of naïve 9-month-old Ab1fl/fl and SPCDAb1 lungs, 
representative of n=3 mice per strain. Scale bar depicts 100 µm.  
Ab1fl/fl SPC6Ab1
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 In summary, at homeostasis AT2 MHCII contributes to the regulation of the 
lung T cell compartment, promoting the development of various antigen-experienced 
T cell subsets. However, its impact is relatively modest in magnitude, only becoming 
apparent in older mice (14 m.o.), and it does not appear to result in overt lung disease. 
 
 
AT2 MHCII contributes to protection from respiratory viral disease 
We next assessed whether AT2 MHCII contributes to the outcome of lung 
infection. To do this, we used two respiratory virus infection models: mouse lung-
adapted PR8 influenza A virus (IAV) as well as Sendai virus (SeV), a natural mouse 
pathogen similar to human parainfluenza virus. To assess the impact of AT2 MHCII 
on viral disease, we measured weight loss of SPCDAb1 and Ab1fl/fl mice after infection 
with either IAV or SeV.  SPCDAb1 and Ab1fl/fl mice demonstrated similar weight loss IAV 
infection (Fig 3.11a, Table 3.1). However, after SeV infection, SPCDAb1 mice on 
average experienced substantially more weight loss and delayed recovery compared 
 
Figure 3.10: Loss of AT2 MHCII does not affect regenerative capacity. a, b, Numbers (a) and 
representative images (b) of lung organoid cultures formed by AT2s sorted from either or Ab1fl/fl 
and SPCDAb1 mice. Data represent n=6 organoid cultures per strain, grown from AT2s originally 
sorted from n=1 mouse per strain. a, Bars represent mean plus SEM, and the data were analyzed 























to the Ab1fl/fl group (Fig 3.11b, Table 3.2). We also assessed the impact of AT2 MHCII 
on mortality after infection with both viruses. SPCDAb1 mice experienced reduced 
survival after IAV infection compared to Ab1fl/fl controls, 24% vs 50% respectively (Fig 
3.11c). Similarly, after SeV infection, SPCDAb1 mice had worse survival with 
approximately 2-fold higher mortality (28%) compared to the Ab1fl/fl controls (12%) (Fig 
3.11d). Of note, here we display the aggregate analyses of multiple independent 
experiments, between which we did observe some variability in disease outcome; in 
some experiments the disease severity differences between the SPCDAb1 and Ab1fl/fl 
mice were more pronounced, and in others less so (Fig 3.12).  
 
Figure 3.11: Loss of AT2 MHCII results in greater weight loss and reduced survival after 
respiratory viral infection. a-d, Comparison of Ab1fl/fl and SPCDAb1 mice after infection with 
influenza strain PR8 (IAV PR8) (a,c) and Sendai virus strain 52 (SeV 52) (b,d). a,b, Weight loss 
with weights displayed relative to day of infection; n=43-53 mice per strain pooled from 6 
independent experiments (a), and n=17-22 mice per strain pooled from 2 independent 
experiments (b). c,d, Mortality, with curves representing proportion surviving; n=21-22 mice per 
strain pooled from 2 independent experiments (c), and n=17-22 mice per strain pooled from 2 
independent experiments (d). a,b, Data are mean plus SEM, analyzed by mixed-effects model 
with post-hoc multiple comparisons with Sidak’s correction at each dpi. P values displayed 
represent overall model effects. Full statistical test results are in Tables 3.1 and 3.2. c,d, Survival 
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Figure 3.12: Differences in weight loss and survival between Ab1fl/fl and SPCDAb1 mice were 
subject to experiment to experiment variation.  a-d, Representative independent experiments 
of Ab1fl/fl and SPCDAb1 mice after infection with influenza strain PR8 (IAV PR8) (a,c) and Sendai 
virus strain 52 (SeV 52) (b,d). a,b, Weight loss with weights displayed relative to day of infection; 
n=6-12 mice per strain (a, left), n=7-12 mice per strain (a, right), n=8-11 mice per strain (b, left), 
and n=9-11 mice per strain (b, right). c,d, Mortality, with curves representing proportion surviving; 
n=9-10 mice per strain (c, left), n=12 mice per strain (c, right), n=9-11 mice per strain (d, left), 
and n=8-11 mice per strain (d, right). a-d, Data are mean plus SEM of mice within one experiment 























































































































We next asked whether AT2 MHCII antigen presentation might contribute to 
the control of viral replication, by measuring lung virus titers after infection with either 
IAV or SeV. There were no significant differences in IAV titers 7 days after infection 
between SPCDAb1 and Ab1fl/fl mice (Fig 3.13a). Similarly, SeV titers 4, 7, and 9 days 
after infection were similar between the two strains (Fig 3.13b).  As LAG3 has been 
shown to restrict lung CD4+ and CD8+ T cell responses during respiratory viral 
infections [160, 161], we also considered whether AT2 MHCII is required for LAG3-
mediated T cell suppression during infection. However, we found similar frequencies 
and numbers of LAG3+ CD4+ and CD8+ T cells in the lungs of SPCDAb1 and Ab1fl/fl mice 
9 days after IAV infection (Fig 3.14). Thus, MHCII on AT2s serves to reduce morbidity 
and mortality in the setting of respiratory viral illness, without impacting LAG3+ T cell 
expansion or lung viral burden. 
 
Figure 3.13: Loss of AT2 MHCII does not affect lung virus titers after respiratory viral 
infection. Comparison of Ab1fl/fl and SPCDAb1 mice after infection with influenza strain PR8 (IAV 
PR8) (a) and Sendai virus strain 52 (SeV 52) (b). Lung virus titers on the days post-infection (dpi) 
indicated; n=7 mice per strain from 1 experiment (a), and n=5 mice per strain for days 4 and 9, 
n=11-12 per strain for day 7, pooled from 2 independent experiments (b).  Bars are mean plus 
SEM of log10 transformed values, analyzed by unpaired two-tailed Student’s t-test (a), and two-
way ANOVA (genotype effect: P=0.2197) with post-hoc multiple comparisons with Sidak’s 







































In summary, these studies suggest that in vivo AT2 MHCII expression confers 
an appreciable advantage in respiratory viral disease outcome. 
  
 
Figure 3.14: Loss of AT2 MHCII does not alter frequencies of LAG3+ T cells after influenza 
virus infection. a,b Ex vivo flow cytometry analysis of LAG3 expression by CD4+ and CD8+ T 
cells in Ab1fl/fl and SPCDAb1 mice. Frequency and number of lung LAG3+ CD4+ (a) and CD8+ (b) T 
cells 9 days post IAV infection; n=6 mice per strain from 1 experiment. Data shown are mean plus 
























































Table 3.1: Mixed-effects model analysis results for weight loss after IAV infection. Results 
of repeated measures mixed-effects model (REML) analysis with Geisser-Greenhouse 
correction factoring in both genotype and day post IAV infection as variables, with post-hoc 
multiple comparisons with Sidak’s correction between the strains at each time point post 
infection. P values for the overall effects as well as for each post-hoc comparison are reported, 
calculated based on weights expressed as a percentage of initial weight. Data depicted in this 
table are in Figure 3.11a. 




Genotype x Time 0.0002 
 
 
Post-hoc comparison results by day 














Post-hoc comparison results by day 






















Genotype x Time <0.0001 
 
 
Table 3.2: Mixed-effects model analysis results for weight loss after SeV infection. Results 
of repeated measures mixed-effects model (REML) analysis with Geisser-Greenhouse 
correction factoring in both genotype and day post SeV infection as variables, with post-hoc 
multiple comparisons with Sidak’s correction between the strains at each time point post 
infection. P values for the overall effects as well as for each post-hoc comparison are reported, 
calculated based on weights expressed as a percentage of initial weight. Data depicted in this 
table are in Figure 3.11b. 
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3.3 Discussion 
Here we demonstrate that AT2 MHCII modestly improves the outcome of 
respiratory virus disease in vivo, and that it also contributes to an increase in antigen-
experienced T cells at homeostasis. 
Given that AT2s constitutively express MHCII, we were surprised to find that 
mice lacking AT2 MHCII did not exhibit overt clinical disease at homeostasis in our 
studies. However, we did observe that the loss of AT2 MHCII resulted in alterations in 
lung T cell phenotypes in aged mice. We found that 14-month-old mice lacking AT2 
MHCII had lower frequencies of lung memory CD4+ and CD8+ T cells and higher 
frequencies of naïve T cells. Furthermore, in SPCDAb1 mice, fewer lung T cells 
expressed markers of activation or proliferation, and fewer CD4+ T cells had 
developed into Tregs, compared to Ab1fl/fl mice. All these observations are consistent 
with either less T cell activation/antigen-encounter overall, or less proliferation or 
survival of antigen-experienced T cells, in the lungs of SPCDAb1 mice. We did not 
observe the same impact on T cell phenotypes in the spleen – differences were 
smaller, if not absent – suggesting that the impact on T cells in SPCDAb1 mice is 
primarily in the lung. The most likely mechanistic explanation is that, at homeostasis, 
AT2 MHCII antigen presentation to CD4+ T cells enhances the local expansion and/or 
survival of antigen-specific CD4+ T cells in the lungs. As CD4+ T cell help is critical for 
the development of memory CD8+ T cells [162-164], this AT2 MHCII-dependent CD4+ 
T cell expansion would also promote lung CD8+ T cell memory formation; this is 
consistent with our observations that Ab1fl/fl control mice demonstrate higher levels of 
activated and memory CD8+ T cells, in addition to CD4+s, compared to SPCDAb1 mice. 
Overall, our data suggest that, at homeostasis, local AT2 MHCII antigen presentation 
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promotes an increase in both antigen-experienced CD4+ and CD8+ T cells in the lungs. 
We did not observe the same alterations to lung T cells in 7-month-old SPCDAb1 
mice, nor did we observe any histological evidence of lung disease in 9-month-old 
SPCDAb1 mice. One potential reason for this is that the specific pathogen free (SPF) 
homeostasis environment of our mouse colony is characterized by artificially low levels 
of antigen. Thus, the putative antigens presented by AT2 MHCII at homeostasis to 
lung CD4+ T cells are limited to the narrow range of inhaled environmental antigens 
present under SPF conditions. The restricted nature of these homeostatic exposures 
may explain why we only observed significant impacts on the lung T cell compartment 
in 14-month-old, but not 7-month-old adult mice; it is likely that a longer duration of 
this low level antigen exposure is needed for the differences in T cell activation to 
become amplified. Along these lines, as our lung histological analyses demonstrating 
the absence of lung disease in SPCDAb1 mice were performed in 9-month-old mice, it 
is possible that these studies were undertaken at too young an age; if lung pathology 
were assessed at an older age, for example when T cell alterations are readily 
apparent, it is possible that histological disease would be present. However, it is also 
possible that under SPF conditions of such restricted antigen encounter, the modest 
lessening in T cell activation and memory formation we observed would not lead to 
lung disease even at an advanced age. Alternatively, it is also possible that even in 
more physiologic situations of abundant environmental antigen encounter, the 
contribution of AT2 MHCII may still be accessory, impacting lung T cell phenotypes, 
but in a manner too small to result in true lung disease at homeostasis.  
Overall, our data suggest that AT2 MHCII contributes to the development of 
antigen-experienced memory, activated, and regulatory T cells in the lung at 
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homeostasis. While the impact we observed was statistically significant, it represented 
an overall modest change in T cell subset frequencies, and it did not result in lung 
disease. We further expand on the potential reasons for this and the potential role for 
AT2 MHCII at homeostasis in more detail in chapter 5.  
Although the effect was not dramatic and not observed in all experiments, we 
nonetheless found that, on average, AT2 MHCII also confers some degree of 
protection in the setting of primary respiratory virus infection, particularly for survival. 
Although the mechanism underlying this effect is still under active investigation, the 
most likely explanation is that it is CD4+ T cell mediated. CD4+ T cells play a number 
of important roles during the primary response to respiratory virus infections that could 
be affected by the loss of MHCII AT2.  
CD4+ T cells have been demonstrated to be cytolytic during influenza virus 
infections [119] and can facilitate complete flu and Sendai viral clearance in CD8+ T 
cell-deficient mice [165, 166]. Thus, one possibility is that AT2 MHCII facilitates CD4+ 
T cell recognition and killing of AT2s, which are major targets of infection in vivo, 
thereby leading to faster viral clearance and improved diseased outcomes. While this 
potential cytolysis may indeed be lost in SPCDAb1 mice, it does not appear to be 
necessary for viral clearance or to substantially change virus loads in our studies (Fig 
3.13), corroborating prior work demonstrating that nonhematopoietic cell MHCII 
expression is not required for clearance of influenza virus infection [167]. Thus, loss 
of CD4+ T cell cytolysis of infected AT2s is an unlikely explanation for the worse 
disease we observed in SPCDAb1 mice.   
Another function of CD4+ T cells during primary infection is to provide help to 
CD8+ T cells, which are the major drivers of viral clearance during infection. The 
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similarity in virus loads between mice with and without AT2 MHCII in both infection 
models (Fig 3.13) suggests that CD8+ T cell cytolytic function is not substantially 
altered. Whether or not this means that CD4+ T cell help to CD8+ T cells is also 
unaffected by loss of AT2 MHCII is unclear. Mice deficient in CD4+ T cells exhibit 
essentially normal viral clearance in both primary influenza and Sendai virus 
infections; although CD8+ T cells may exhibit poorer per-cell cytotoxicity [168], virus 
clearance in only slightly delayed [166, 168-171]. Thus, it is possible that CD4+ T cell 
help is suboptimal in the absence of AT2 MHCII but this may not be manifest in bulk 
virus titers at the time points studied. Even if CD4+ T cell help is impaired in SPCDAb1 
mice, given that CD8+ viral clearance seems to remain intact, poor CD4+ T cell help to 
CD8+s is unlikely to account for the increased mortality observed in our studies. 
As virus titers were not affected by the loss of AT2 MHCII, it is possible that, 
instead of an inadequate antiviral response, the lack of AT2 MHCII results in increased 
immunopathology, which is what then leads to worse survival. Indeed, key future 
histological studies will assess whether the increased mortality that results from loss 
of AT2 MHCII is associated with more severe lung damage and inflammation. One 
mechanism by which a loss of MHCII could exacerbate inflammatory damage would 
be via a LAG3-dependent mechanism. The T cell inhibitory receptor LAG3 contributes 
to the restriction of T cell responses during Sendai and influenza virus infections [160, 
161], and MHCII is its major ligand; if MHCII specifically on AT2s is a primary ligand 
for  these antiviral T cells in the lung, then the loss of this inhibitory checkpoint would 
result in excessive T cell expansion and inflammation. However, we demonstrated 
similar numbers and frequencies of LAG3+ CD4+ and CD8+ T cells in mice with and 
without MHCII on AT2s during infection, suggesting that AT2 MHCII is not required to 
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regulate this population. Thus, loss of LAG3-mediated T cell suppression is unlikely to 
account for the worse disease in SPCDAb1 mice.  
Another mechanism by which loss of AT2 MHCII could result in 
immunopathology is by altering the cytokine production characteristics of lung 
infiltrating CD4+ T cells. Although CD4+ T cells are primed in the lymph nodes to 
develop into a particular Th phenotype, Th1 in the case of Sendai and influenza viral 
infections, their functional properties retain some degree of plasticity and can be 
further modified at the site of infection in the effector phase [6, 15, 16, 120, 121]. Thus, 
it is possible that AT2s help to reinforce Th1 CD4+ phenotype and facilitate the 
development of a protective CD4+ T cell cytokine milieu. Future studies will assess 
whether loss of AT2 MHCII results in changes to the quality of CD4+ cytokine 
production, for example skewing towards the production of Th2 or Th17 cytokines that 
are associated with immunopathology [4, 5, 172].    
A final possibility is that AT2 MHCII helps to facilitate proper CD4+ T cell 
localization during infection to specific regions within the lung experiencing high virus 
loads. Thus, AT2 MHCII may not directly lead to changes in CD4+ T cell number or 
function, but instead may help to distribute them to sites experiencing particularly 
severe alveolar damage. Previous studies demonstrate that during lung injury, CD4+ 
Tregs help to facilitate lung repair by enhancing AT2 proliferation [173, 174]. Thus, it 
is possible that AT2 MHCII helps to facilitate disease recovery and prevent mortality 
by targeting CD4+ T cells to the areas most in need of healing. Future imaging studies 
will address this localization question.  
Overall, although we did observe that loss of AT2 MHCII results in worse 
survival during flu and Sendai virus infections, which may occur via the potential 
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mechanisms just described, the effects were modest and not always consistent. One 
possible explanation for this small effect is that in situations of inadequate CD4+ T cell 
function – failure to develop cytotoxic capacity, failure to provide CD8+ T cell help, low 
Th1 cytokine production – other immune mechanisms can compensate to fill the void 
and facilitate recovery, masking the defect.  Indeed, during primary flu or Sendai virus 
infections, even mice totally deficient in CD4+ T cells experience similar disease and 
mortality to wild-type mice, with almost normal virus clearance kinetics [166, 168-171] 
(although, importantly, these studies were done with less pathogenic strains of 
influenza and Sendai virus). Thus, it is possible that looking at clinical outcomes such 
as mortality and weight loss during primary respiratory virus infection will not capture 
even large differences in CD4+ T cell function that result from the loss of AT2 MHCII.  
Another explanation for the small benefit afforded by AT2 MHCII is that the contribution 
is truly small, that AT2 MHCII does not alter the CD4+ T cell response to a significant 
degree. To understand which of these explanations is more likely, a more extensive 
characterization of the antiviral CD4+ T cell response and CD4+ T cell functionality and 
localization in mice with and without AT2 MHCII is needed and will be a major focus 
of future study. Additionally, as discussed in chapter 5, we will explore other disease 
models in which CD4+ T cell dysfunction may be more impactful and phenotypically 
apparent. 
We observed experiment-to-experiment variability in viral infection disease 
outcome, particularly weight loss; in some experiments, SPCDAb1 mice exhibited 
substantially worse weight loss compared to controls, but in other experiments they 
were similar (Fig 3.12). In this dissertation we have displayed the averages and 
aggregated data across all of these experiments to best summarize the consequences 
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of loss of AT2 MHCII that we observed, but we still do not fully understand the reason 
for such variability between experiments. The most likely explanation is that there is 
an additional modifying or contributing factor that exacerbates the impact of AT2 
MHCII loss; when this factor is present, the additional loss of AT2 MHCII causes 
SPCDAb1 mice to have more severe disease, but when it is not, absent AT2 MHCII 
expression is not sufficient to induce a worse phenotype. We explored various 
explanations as to what this stochastic variable could be including mouse age, sex, 
starting weight, age of tamoxifen administration, time between tamoxifen 
administration and infection, and time of day at which the mice were infected. None of 
these parameters appeared to explain the instances in which SPCDAb1 mice 
experience more or less severe disease compared to controls.  One additional 
possibility we considered was the effect of humidity, as this has been shown to alter 
influenza disease severity [175]; however, the humidity in the animal facilities is 
carefully controlled, and we observed variability in disease outcome in some 
experiments that were performed only days apart. Another potential modifier that we 
considered but have not yet explored is temporal changes in the microbiome, which is 
heterogeneous in the lung across time and between mice [176], and can alter their 
susceptibility to respiratory viral infections [177].   
Another possible reason for the experiment to experiment variability we 
observed could stem from caveats in the mouse model we used for these experiments. 
As shown in Fig 3.2, mice of the floxed I-Ab background, regardless of Cre expression, 
demonstrate heterogeneous and, on average, lower MHCII expression by a variety of 
MHCII-expressing cell types compared to mice without floxed MHCII alleles. This 
floxed I-Ab background alone increases disease severity in the mice; compared to 
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SPCCre mice, the Ab1fl/fl controls look overtly more hunched, ruffled, and inactive, and 
also exhibit more severe weight loss and mortality, as well as somewhat slower viral 
clearance, after infection (Fig 3.15), even though both have intact AT2 MHCII 
expression. Based on this observation, we used Ab1fl/fl mice as controls for the 
SPCDAb1 mice in our experiments since both are subject to this floxing effect; however, 
this heterogeneity in APC MHCII expression afforded by the floxed I-Ab background 
could have contributed the differences in disease severity we observed. A major 
reason for the inter-experiment variability we experienced was that the Ab1fl/fl control 
mice exhibited different disease severity from experiment to experiment, which made 
the differences relative to SPCDAb1 mice bigger or smaller; it is possible that variable 
MHCII expression  on key APCs from the floxed I-Ab background between experiments 
contributed to different disease outcomes in the Ab1fl/fl strain. It is also possible that 
there are additive effects with these alterations and loss of AT2 MHCII in the SPCDAb1 
mice; for example, perhaps loss of AT2 MHCII is particularly impactful on disease 
outcome in the mice with especially low DC or B cell MHCII expression from the floxed 
I-Ab background. Given these considerations, an important avenue of future work in 
our laboratory will be to generate a new strain of floxed I-Ab mice that do not exhibit 
the same global disruptions to MHCII expression, which will ideally serve as a 
“cleaner” system to isolate just the impact of AT2 MHCII. 
 70 
In summary, we observed that loss of AT2 MHCII resulted in lower proportions 
of memory, activated, and regulatory phenotype lung T cells at homeostasis, although 
this effect was only apparent in in aged mice and did not result in overt lung disease. 
In the setting of respiratory virus infection, we found that, on average, the loss of AT2 
MHCII results in modestly increased weight loss and mortality. As previously 
discussed, there are a variety of potential mechanisms underlying the effects of AT2 
 
Figure 3.15: Ab1fl/fl control mice exhibit worse weight loss and disease and delayed viral 
clearance compared to SPCCre control mice after virus infection. a-d, Comparison of Ab1fl/fl 
and SPCCre mice after infection with influenza strain PR8 (IAV PR8) (a) and Sendai virus strain 
52 (SeV 52) (b-d). a,b, Weight loss with weights displayed relative to day of infection; n=21-27 
mice per strain pooled from 3 independent experiments (a), and n=17-20 mice per strain pooled 
from 2 independent experiments (b). c, Mortality, with curves representing proportion surviving; 
n=17-20 mice per strain pooled from 2 independent experiments. d, Lung virus titers on the days 
post-infection (dpi) indicated; n=5 mice per strain for days 4 and 9, n=5-11 per strain for day 7, 
pooled from 2 independent experiments. Bars are mean plus SEM of log10 transformed values. 
a,b, Data are mean plus SEM. Mortality and viral titers of SPCCre mice after IAV PR8 infection 
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MHCII we observed in vivo, both in terms of how its effects could be mediated and 
why its impact is relatively small. In the next chapter, I more closely examine the latter, 
by more rigorously and directly assessing the capacity of AT2s to present antigen via 
MHCII to CD4+ T cells. 
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CHAPTER 4:  
TYPE II ALVEOLAR CELLS EXHIBIT RESTRAINED MAJOR 
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In the previous chapter, we demonstrated that loss of AT2 MHCII results in 
more severe disease in the setting of respiratory virus infection. Furthermore, we 
observed that in the absence of AT2 MHCII at homeostasis in aged mice, higher 
proportions of lung CD4+ and CD8+ T cells remain naïve to antigen encounter. 
However, the impact of AT2 MHCII was relatively modest in both cases. In 3.3 and 
5.6, we discuss potential explanations for these small effects, relating to caveats of 
the particular homeostasis and disease models we used. However, in this chapter, 
we also explore the possibility that the more restrained impact of AT2 MHCII in vivo 
results from limited AT2 MHCII presentation to CD4+ T cells. 
Other groups have explored AT2 MHCII antigen presentation previously, but 
their reports have been conflicting [106-108, 110]. Furthermore, in these prior 
studies it is difficult to discern the true MHCII antigen presentation capacity of AT2s 
for several reasons, discussed at length in 4.3 with key limitations mentioned here 
briefly. One major consideration is that in all previous studies, CD4+ T cell activation 
is used as the main read out of AT2 MHCII presentation; however, CD4+ T cell 
activation can also be influenced by factors other than MHCII presentation, primarily 
by costimulation, and this was only controlled for directly in one prior study [110].  
Furthermore, in no prior studies was AT2 MHCII presentation compared directly to 
that of professional APCs, and in no case was the amount of available source 
antigen quantified. Therefore, the relative efficiency and magnitude of AT2 MHCII 
presentation is still largely unknown. Thus, here we more rigorously examine the 
capacity of AT2s to present antigen via MHCII, comparing to professional APCs, 
both in vitro and in vivo in multiple antigen systems.  
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4.2 Results 
AT2s exhibit restrained antigen presentation capacity via MHCII 
Although loss of AT2 MHCII worsened respiratory virus disease, the effect was 
smaller than anticipated based on the abundance of AT2s in the lung [111] and the 
magnitude of AT2 MHCII expression. A potential explanation is limited MHCII antigen 
processing and presentation by AT2s, which would be advantageous in constraining 
the amplification of inflammatory T cell responses that could disrupt the lung gas-
exchange parenchyma. 
To investigate the antigen presentation function of AT2s, we first evaluated the 
ability of AT2s to stimulate flu peptide/MHCII complex-specific costimulation-
independent T cell hybridomas (Fig 4.1a). AT2 presentation of five different epitopes 
from live virus was undetectable (Fig 4.1b,c), in contrast to professional APCs that 
presented all five. Poor presentation by AT2s was not due to a failure of in vitro 
infection, as AT2s were infected to levels higher than comparator professional APCs 
(Fig 4.2).  Limited presentation was observed across multiple MHCII alleles, B6 I-Ab 
(Fig 4.1b) and BALB/c I-Ed (Fig 4.1c), was not the result of protein source, as both 
HA and NA-derived epitopes were similarly affected (Fig 4.1b, c), and was similar for 
epitopes generated by both exogenous (HA107-119) and endogenous (NA79-93) 
processing pathways [178] (Fig 4.1c). Even when pulsed with synthetic peptides, 
AT2s were able to present only three out of five epitopes (HA91-107, HA302-313, NA79-93) 
(Fig 4.1b,c). Thus, AT2s exhibited a global impairment in the capacity to present 













Figure 4.1: AT2s exhibit a globally restricted capacity to present individual influenza virus 
epitopes via MHCII in vitro. a, Schematic of hybridoma presentation assay. b,c, Presentation of 
MHCII-restricted flu peptides by B6 AT2s and a mixed population of CD11c+ and CD19+ lung cells 
(b) or BALB/c AT2s and CD11c+ lung cells (c) sorted from naïve mice then incubated with synthetic 
peptide or live virus, reflected by NFAT-LacZ-inducible T cell hybridoma activation and cleavage 
of a fluorogenic b-galactosidase substrate; bars shown represent 3 technical replicates plus SEM 
from 1 experiment, representative of 3 similar independent experiments for (b). 
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Assays of AT2 function in vitro may be suboptimal due to reduced viability after 
cell sorting and the gradual de-differentiation of AT2s in standard tissue culture [179, 
180]. Additionally, measuring presentation on an individual epitope basis may 
underestimate the presentation of all possible MHCII-restricted flu peptides. Thus, we 
next examined AT2 in vivo flu peptide/MHCII complex formation, by co-culturing in 
vivo-infected AT2s from wild-type or MHCII-/- B6 mice taken 4 days post influenza 
infection with polyclonal splenic CD4+ or CD8+ T cells taken 9 days post-infection, in 
the presence of soluble anti-CD28 (Fig 4.3a). MHCII presentation was detected via T 
cell IFNg production captured by ELISpot. AT2s from flu-infected mice were capable 
of stimulating both CD4+ and CD8+ T cells to produce IFNg (Fig 4.3b). Stimulation of 
CD4+ T cells, but not CD8+ T cells, was abrogated when MHCII-/- flu-infected AT2s 
were used as APCs, confirming that stimulation of CD4+ T cells by AT2s was MHCII-
dependent.  However, consistent with our in vitro studies, AT2 presentation to CD4+ T 
 
Figure 4.2: AT2s are robustly infected with influenza virus in vitro. Surface influenza 
hemagglutinin (HA) expression by B6 AT2s (top) and a mixed population of CD11c+ and CD19+ 
lung cells (bottom) sorted from naïve mice then incubated with no antigen (left) or live virus (right) 
in vitro for 14h. These plots reflect the APCs used in the hybridoma assay in Figure 4.1b. The 
frequency of HA+ cells is shown above the gates, which were drawn based on the no antigen 
conditions. Two different fluorophore conjugated versions of the same anti-HA antibody were used 
because the AT2 and CD11c+/CD19+ populations were already labeled with different fluorophores 
(APC and FITC, respectively) from the cell sorting process. 
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cells was markedly less efficient than professional APCs, in this case CD103+ CD11c+ 
cells taken from the same lungs; despite being 9 times more infected, AT2s (99% 
infected, Fig 4.4) stimulated less than half the IFNg production than the comparator 






Figure 4.3: In vivo-infected AT2s exhibit poor presentation of influenza virus epitopes to 
polyclonal CD4+ T cells via MHCII. a, Schematic of primary T cell ELISpot presentation assay. 
b, Presentation of MHCII-restricted flu peptides by lung AT2s and CD103+ CD11c+ APCs sorted 
from naïve or flu-infected WT or MHCII-/- B6 mouse lungs 4 dpi, measured as the production of 
IFN-g by responding flu-experienced splenic CD4+ and CD8+ T cells (as indicated); “APC %flu+” 
numbers describe the proportion of each APC type that was flu-infected (shown in Fig 4.4), and 
bars shown represent 1-3 technical replicates plus SEM from 1 experiment, representative of 2-3 





























0 0 99 99 96 98 0 0 11 9 6 4
AT2 CD103+ CD11c+
+CD4 +CD8 +CD4 +CD4 +CD8





We considered that the high degree of AT2 infection in our assays might impair 
their capacity to process and present antigen.  To address this, we measured MHCII 
antigen presentation using a non-infectious model system, by staining lungs directly 
ex vivo with the peptide/MHCII complex-specific “YAe” antibody [181] (Fig 4.5a). YAe 
detects Ea52-68/I-Ab complexes, which form in [BALB/c x B6] F1 mice as they are 
composed of a peptide from I-Ed (BALB/c-derived) presented by I-Ab (B6-derived). In 
naïve F1 mice, AT2s had low yet detectable YAe staining above the background levels 
of B6 AT2s (Fig 4.5b,c). However, YAe staining of F1 AT2s was significantly lower 
than that of F1 lung B cells (Fig 4.5b,c). This could not be explained by differences in 
expression of the source proteins, I-Ab and I-Ed, which are similarly expressed by AT2s 
and B cells at homeostasis, if not slightly higher in AT2s (Fig 4.6a,b). These results 
indicate that AT2s are capable of forming Ea52-68/I-Ab complexes at steady state, but 
they do so far less efficiently than do B cells. 
 
 
Figure 4.4: AT2s are robustly infected with influenza virus in vivo. Intracellular influenza 
nucleoprotein (NP) expression by B6 AT2s (top) and CD103+CD11c+ lung cells (bottom) sorted 
from naïve or flu-infected WT or MHCII-/- B6 mouse lungs 4 dpi and incubated with CD4+ and CD8+ 
T cells in vitro for 14h (as indicated). These plots reflect the antigen presenting cells used in the 
ELISpot presentation assay illustrated in Figure 4.3b. The frequency of NP+ cells is shown above 
the gates, which were drawn based on the naïve conditions. 
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To better approximate the setting of viral infection, we also treated mice with IFNg 
and then measured Ea52-68/I-Ab complex formation. AT2 YAe staining was significantly 
increased in F1 mice after treatment with IFNg, but was again lower than B cells in the 
same mice (Fig 4.5b,c). To assess the contributors to increased MHCII presentation 
in AT2s, we evaluated changes in expression of I-Ab, I-Ed, and H2M, all of which are 
required for Ea52-68/I-Ab complex formation [80]. Both I-Ab and I-Ed increased in AT2s 
after IFNg administration (Fig 4.6a,b). IFNg also induced some AT2s to express 
 
Figure 4.5: AT2 MHCII presentation capacity is enhanced in the setting of inflammation but 
remains limited. a, Schematic of YAe presentation assay. b,c, Ea52-68/I-Ab complex formation by 
AT2s and B cells, detected by ex vivo YAe antibody staining of lungs from WT B6 or F1 [BALB/c 
x B6] mice treated with PBS or IFNg. b, Plots represent n=4-6 mice per group total from 2 
independent experiments. c, Bars represent mean plus SEM and depict n=2-3 mice per group 
from 1 experiment, representative of 2 similar independent experiments (total n=4-6). Data were 
analyzed by three-way ANOVA with multiple comparisons with Sidak’s correction. P values 
displayed represent post-hoc comparisons of interest. 
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H2Mab2, which is absent at baseline (Fig 4.6c,d). Although H2Mab2+ AT2s exhibited 
more YAe staining than H2Mab2- AT2s, both populations stained highly (Fig 4.6e), 
suggesting that a higher magnitude of H2M contributes to enhanced Ea52-68/I-Ab 
presentation, but the specific H2Mab2 isoform is not required. Thus, AT2 MHCII 
presentation increases during IFNg inflammation due to the upregulation of several 
MHCII presentation mediators, but it is still less efficient than that of professional 
APCs.  
Taken together, these data demonstrate that AT2s are capable of presenting 
antigen via MHCII to CD4+ T cells, and this is enhanced in the setting of inflammation; 
however, compared to professional APCs they exhibit limited antigen presentation of 
MHCII-restricted epitopes derived from both viral and endogenous proteins, as well as 
some extracellular peptides. This restrained presentation capacity may explain the 
variability seen in prior studies of AT2 function owing to differences in the model 
systems used, in particular the level of antigen provided to the AT2s, as well as the 
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Figure 4.6: Expression of I-Ab, I-Ed, and H2M in AT2s increases after in vivo treatment with 
IFN-g, but does not explain poor MHCII presentation. a,b, I-Ab (a) and I-Ed (b) expression by 
AT2s and B cells, detected by ex vivo flow cytometry staining of lungs from MHCII-/- (II-/-) B6 (a), 
WT B6 (b), or F1 (a,b) mice treated with PBS or IFNg (as indicated). c,d, Intracellular H2Mab2 
expression by AT2s and lung B cells from F1 or H2-DMa-/- (Ma-/-) B6 mice treated with PBS or 
IFNg. Frequency of H2Mab2+ cells is shown above gates (c), which were drawn separately for 
AT2s and B cells based on corresponding H2-DMa-/- cells. e, YAe staining of H2Mab2+ and 
H2Mab2- subpopulations of AT2s from B6 and F1 mice treated with IFNg. c, Plots represent n=4-
6 mice per group total from 2 independent experiments. a,b,d,e, Bars represent mean plus SEM 
and depict n=2-3 mice per group from 1 experiment, representative of 2 similar independent 
experiments (total n=4-6) (d,e) or n=1-3 mice per group from 1 experiment (a,b). Data were 
analyzed by two-way ANOVA with multiple comparisons with Tukey’s correction (a,b,d), and 




Here we demonstrate that, in contrast to professional APCs, AT2s exhibit a 
program of globally restrained MHCII antigen presentation. We believe that our 
findings represent the most accurate and definitive study of AT2 MHCII antigen 
presenting function to date, in comparison to conflicting prior reports on this subject, 
for the reasons outlined below. 
In our assays, we used FACS to isolate AT2s, based on published cell surface 
markers [105] that we also validated in house (Fig 6.1). Using this method, we 
routinely obtained purities of >95%. Thus, our studies likely reflect the activities of 
AT2s rather than contaminating cells. 
When cultured on plastic dishes in vitro, AT2s lose their defining characteristics 
and de-differentiate within a few days [144, 179, 180]. We took great care to avoid this 
issue, by assessing AT2 presentation capacity directly ex vivo with no in vitro 
maintenance required (YAe), or in in vitro co-cultures lasting no longer than 
approximately 14 hours (hybridomas, ELISpot).  Furthermore, in two different 
approaches (YAe, ELISpot), we measured AT2 peptide/MHCII complexes that formed 
in vivo, to avoid artificial defects in AT2 MHCII presentation of in vitro-encountered 
antigens that might be an artifact of the instability of AT2 function in vitro.  
In assays where MHCII antigen presentation is detected by CD4+ T cell 
activation, the provision of costimulation is a critical modifier; failure to see CD4+ T cell 
activation by an APC thus can result either from poor MHCII presentation or from a 
lack of costimulation. We avoided this confounding factor by using experimental 
approaches that were independent of AT2-derived costimulation; T cell hybridomas 
do not require costimulation, we provided exogenous anti-CD28 antibody to the 
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ELISpot assay, and the YAe antibody is a direct readout of Ea52-68/I-Ab complexes. 
Thus, in our studies we feel confident that we were able to isolate the effects of just 
AT2 peptide/MHCII complex formation from the effect of costimulatory signals. 
Another factor that directly impacts MHCII antigen presentation of a given 
epitope is the availability of the source antigen to the APC. For example, an APC may 
be highly capable of presenting a particular epitope, but if it expresses very low levels 
of the source protein, then peptide/MHCII presentation will be low. In our assays, we 
were able disentangle these influences by quantifying the antigen burden in our APCs 
of interest; we measured levels of influenza virus infection (hybridomas, ELISpot) and 
also quantified the levels of I-Ab and I-Ed (Yae) in AT2s and comparator APCs. Thus, 
we are able to interpret true efficiency of MHCII antigen presentation relative to the 
amount of available antigen.  
Finally, MHCII antigen presentation capacity can be viewed on a global scale 
and also in relation to one particular epitope. For example, based on the expression 
of relevant processing mediators, an APC could exhibit poor ability to generate a wide 
diversity of MHCII-restricted epitopes (poor global MHCII presentation), but could still 
able to present a few specific peptide/MHCII complexes (efficient epitope-of-interest 
presentation). In our studies, we measured both bulk AT2 MHCII presentation to 
polyclonal CD4+ T cells, as well as the presentation of specific I-Ed and influenza 
derived epitopes.  Thus, we were able to capture MHCII presentation by AT2s at the 
individual epitope level and on a broader scale by assessing multiple antigen systems 
and polyclonal responses. 
The variability in prior reports of AT2 MHCII antigen presentation capacity and 
its impact on CD4+ T cell activation likely result from a combination of technical 
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limitations and differences in how the studies were performed, particularly in relation 
to the considerations discussed above. In previous studies of AT2 MHCII presentation, 
the methods used to isolate AT2s were variable, as were the purities obtained. 
Cunningham et al. used differential centrifugation combined with magnetic bead 
depletion to isolate human AT2s; while they do not report the exact AT2 purity, it is 
likely lower than that achieved by FACS [110]. Subsequent studies in mice also used 
either magnetic beads or FACS for isolation, with purities ranging widely from 70% to 
>95% [106-108]. Furthermore, most of these studies focused on in vitro AT2 
processing and presentation, in which AT2s were placed in culture for extended 
periods of time, from 48 hours up to 5 days, and at the assay endpoints AT2 cells were 
not analyzed to assess the maintenance of AT2 phenotypic integrity. Additionally, 
different types of CD4+ T cells used between these studies – T cell hybridomas, 
primary naïve T cells, and primary effector T cells – likely contributes to the variation, 
as these T cells differ in their requirement for costimulatory signals, and the role of 
costimulation was not directly isolated or examined, except for in one study [110]. 
Finally, different model systems employed by each study likely results in widely 
differing amounts of antigen available to the AT2s for processing and presentation, 
and also depends on the analysis of distinct epitopes of interest between studies. In 
none of these studies was antigen availability to AT2s directly quantified, and only one 
report assessed AT2 MHCII presentation in the context of more than one antigen 
system (two epitopes total, one from each system) [107]. In summary, the conflicting 
nature of prior reports of AT2 MHCII function likely results from heterogeneity in all of 
these respects.   
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In our work, we have attempted to rigorously address all of these potential 
experimental caveats and shortcomings, and using multiple orthogonal approaches, 
we have demonstrated that AT2s exhibit inefficient MHCII presentation. This limited 
MHCII presentation capacity by AT2s is consistent with the relatively modest impact 
that loss of AT2 MHCII has in vivo described in chapter 3. However, it is surprising 
given that AT2s seem to possess many promising MHCII+ APC characteristics, as 
outlined in chapter 2, which should theoretically render them capable of robust MHCII 
antigen presentation. In the next chapter, I will discuss possible mechanisms 
restricting AT2 MHCII presentation and will offer our perspective on its why such 












CHAPTER 5:  
DISCUSSION AND FUTURE DIRECTIONS  
 
AT2s were first described to express MHCII at homeostasis decades ago. 
Despite this expression being highly unusual behavior for non-professional APC, let 
alone a cell that ostensibly is not part of the formal immune system, very few reports 
over the last 30 years have sought to understand the biological function of MHCII on 
AT2s, and none has explored the mechanisms controlling AT2 MHCII expression. To 
expand our understanding of AT2 MHCII regulation and function, in this dissertation I 
have examined the factors driving steady-state AT2 MHCII expression, the role of 
AT2 MHCII in vivo at homeostasis and during respiratory viral infection, and the 
MHCII antigen presentation capacity of AT2s.  
In chapter 2, I investigated the mechanisms driving AT2 MHCII expression 
and also assessed other APC characteristics of AT2s. I demonstrated that AT2s 
produce their own MHCII protein and that this expression is dependent on the CIITA 
pIV transcription factor. I further showed that, contrary to convention, AT2 MHCII 
expression does not require IFNg, nor does it require a number of other broad 
inflammatory signals including the microbiota. I also found that AT2s possess ample 
APC characteristics aside from constitutive MHCII expression: they are capable of 
exogenous protein uptake and endogenous antigen expression, they possess 
functionally competent classical antigen processing mediators, and they express 
non-canonical costimulatory molecules. Altogether, I demonstrated that AT2s have 
the potential to be robust MHCII+ APCs both at homeostasis and during infection. 
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Based on these promising MHCII+ APC characteristics, in chapter 3, I sought 
to elucidate the in vivo function of AT2 MHCII. I found that loss of MHCII from AT2s 
did not result in clinical or histological lung disease at homeostasis. However, in 
aged mice, the absence of AT2 MHCII resulted in changes to the homeostatic lung T 
cell compartment; higher proportions of lung T cells were naïve, and lower 
frequencies were antigen-experienced, compared to controls. Furthermore, I 
demonstrated that in the setting of lower respiratory tract viral infection, mice lacking 
MHCII on AT2s exhibited greater mortality and weight loss compared to controls. 
However, the impacts at homeostasis and during infection were relatively modest, 
and less than expected based on the magnitude of AT2 MHCII expression and 
abundance of AT2s in the lung. 
In chapter 4, I examined the MHCII antigen presentation capabilities of AT2s. 
I demonstrated that AT2s are capable of processing and presenting both viral and 
self protein antigens via MHCII, but their presentation capacity is substantially limited 
compared to that of professional APCs, even when they have access to significantly 
more epitope source protein and express similarly high levels of MHCII. 
Furthermore, I found that in some cases, AT2s even failed to present synthetic 
peptides. Thus, I found that AT2s exhibit globally restrained MHCII antigen 
presentation capacity, which is consistent with the more measured contribution they 
make via MHCII at homeostasis and to the outcome of lung viral infection as 
observed in chapter 3.  
Below I discuss the implications of these findings and provide insight into key 
future areas of study. 
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5.1 Constitutive MHCII expression paired with restrained antigen presentation: 
a model for AT2 MHCII function tailored to the unique requirements of the lung 
Despite constitutively expressing high levels of MHCII protein similar to 
professional APCs (chapter 2), the MHCII antigen presentation capacity of AT2s is 
substantially limited in comparison (chapter 4). At first glance, it seems that AT2s 
thus exhibit an opposing and counterproductive combination of features. However, I 
suggest that this particular configuration – of high MHCII expression and restricted 
antigen presentation – is advantageous and specifically tailored to the unique 
immune environment of the lung, where excessive T cell activation would be 
especially damaging in comparison to other organs.  
In this model, high MHCII expression poises AT2s to amplify lung adaptive 
immune responses, but restricted MHCII presentation establishes a higher threshold 
that must be overcome in order to do so. Such a system would enable MHCII 
presentation by AT2s to trigger cognate T cell activation only in the setting of high 
antigen burden, such as a severe lung infection, but would prevent excessive AT2-
induced amplification of T cells in response to continuous low levels of inhaled 
innocuous environmental antigens, avoiding what would otherwise be constant 
inflammatory lung damage. Furthermore, even in the setting of high antigen burden, 
restrained presentation would ensure that AT2s amplify T cell responses in a more 
tempered way to prevent excessive inflammation in the lung tissue. Although not 
explored here, this model would suggest that just as the loss of AT2 MHCII resulted 
in worse outcomes after viral infection, artificially increasing AT2 MHCII presentation 
to DC-like levels would presumably also have a detrimental effect. In summary, I 
propose that AT2s possess a unique combination of APC characteristics that are 
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optimized specifically for their organ of residence, to enhance lung immune 
responses but prevent immunopathologic destruction of the delicate gas exchange-
surface that is necessary to sustain life. Overall, this results in a more measured 




5.2 Possible contributors to poor MHCII antigen presentation by AT2s  
I demonstrated in chapter 4 that AT2s exhibit globally impaired capacity to 
process and present antigen via MHCII. This suggests that AT2s possess impairments 
in one or more of the key APC requirements detailed in 1.6: antigen uptake, 
proteolysis, appropriate peptide and MHCII trafficking, and peptide loading. 
AT2s have intact mechanisms of antigen uptake. As demonstrated in Fig 2.7, 
AT2s are capable of endocytosing exogenous antigen, and overall they have robust 
endocytic mechanisms by virtue of their surfactant recycling function [111]. AT2s also 
expressed high levels of the endogenous self and viral proteins containing the 
epitopes whose presentation I measured specifically (Figs 4.2, 4.4, 4.6), and in 
general as the main targets of a variety of lung viral infections [182, 183], they likely 
produce abundant endogenous antigens in those cases as well. 
AT2s also have robust enzymatic processing capacity. They express a number 
of enzymes in the endosomal network that are critical for the appropriate proteolytic 
processing of surfactant proteins, such as Cathepsin H [114, 184]. They also express 
conventional proteases that have been implicated in classical MHCII antigen 
presentation. For example, either Cathepsin S or L can mediate the final steps of 
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invariant chain processing into the CLIP peptide remnant and are important for antigen 
processing, and AT2s express Cathepsin L [24-26, 185]. They also express the 
asparagine endopeptidase (AEP), and the reducing enzyme gamma-interferon-
inducible lysosomal thiol reductase (GILT), both of which play key roles in the 
generation of antigenic epitopes and in the maturation of other antigen processing 
proteases and components [46, 76, 186-189] (Fig 5.1). 
I also showed that AT2s express the conventional MHCII-associated antigen 
presentation mediators H2M and invariant chain (Figs 2.8, 2.9). While these mediators 
are not required for the MHCII presentation of all epitopes, their presence strongly 
suggests that AT2s have intact MHCII trafficking and peptide loading mechanisms. I 
found that AT2s express only one heterodimeric isoform of H2M, H2Mab1, in contrast 
to conventional potent APCs, such as B cells and DCs, which also express H2Mab2 
(Figs 2.9, 2.10, 2.12). This led us to speculate that limited antigen presentation by 
AT2s might result from functional inferiority of H2Mab1 as compared to H2Mab2. 
 
Figure 5.1: AT2s express proteases associated with antigen processing and presentation. 
Cathepsin H (Ctsh), Cathepsin S (Ctss), Cathepsin L (Ctsl), AEP (Lgmn), and GILT (Ifi30), 
transcript abundance measured by bulk RNA-seq, normalized by RPKM, in AT2s from naïve 4 
week old B6 mice. The results shown here are in whole based upon data deposited on the 
LungMAP Consortium by J. Whitsett and Y. Xu. They were downloaded from (www.lungmap.net), 
on Nov 18, 2018. The LungMAP consortium and the LungMAP Data Coordinating Center 
(1U01HL122638) are funded by the National Heart, Lung, and Blood Institute (NHLBI). 
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However, consistent with prior reports [149, 150], I demonstrated that the H2Mab1 
was capable of enabling complete CLIP removal (Fig 2.9), and of facilitating Ea52-68/I-
Ab complex formation (Fig 4.6).  
Thus, AT2s appear to possess all of the requisite MHCII+ APC capabilities and 
do so robustly. However, they nonetheless exhibit restricted presentation. This is 
highly unusual; in prior studies, the Eisenlohr laboratory has found that simply 
transducing skin fibroblasts with CIITA, which induces expression of MHCII, invariant 
chain, and H2M, is enough to render them highly presentation competent [46]. Overall, 
this suggests that there may be mechanisms operating in AT2s that actively oppose 
MHCII presentation.  
The endosomal network of AT2s is highly specialized for the synthesis, 
secretion, and recycling of surfactant [114], as discussed in 1.8. Thus, although AT2s 
have intact endocytic and proteolytic mechanisms that can facilitate MHCII antigen 
presentation, as well as appropriate MHCII trafficking and peptide loading mediators, 
it is possible that their endosomal compartments are so tailored toward surfactant 
production that they are dominantly incompatible with the trafficking, localization, and 
degradation requirements for optimal MHCII presentation. For example, it is possible 
that the proteolytic environments that enable proper surfactant pro-protein processing 
or degradation are too harsh for the preservation of antigenic epitopes, and thus the 
majority of candidate peptides are destroyed before loading. It is also conceivable that 
the endosomal maturation and trafficking pathways optimized for delivery of surfactant 
components to the lamellar body may prevent the efficient transport of antigenic 
peptides to MHCII-containing intracellular compartments.  
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It is also unusual that AT2s express such high levels of MHCII yet present only 
some synthetic peptides when provided exogenously (Fig 4.1). One possible 
explanation is that AT2 MHCII molecules are already bound to a high affinity peptide 
on the cell surface that can be displaced only by even higher affinity peptides.  If such 
a peptide loads onto MHCII during the early stages of intracellular MHCII biosynthesis 
and trafficking, this would explain the poor presentation of protein-derived peptides by 
AT2s as well. One appealing candidate is a surfactant protein derived peptide, such 
as a pro-SP-C or pro-SP-B processing remnant, which would be abundant and present 
in the endosomal compartments where nascent MHCII molecules transit and peptide-
loading generally occurs.  
Understanding the factors limiting AT2 presentation will be an important area 
of future inquiry, and MHCII peptide elution studies are ongoing in order to investigate 
this latter hypothesis. 
 
 
5.3 Drivers of constitutive MHCII expression by AT2s  
I was unable to identify an immune signal required for AT2 MHCII expression 
despite investigating the conventional IFNg axis as well as a variety of broad 
adaptive and innate mediators, including the microbiota. Although I did not examine 
every possibility, this strongly suggests that MHCII expression is not driven by 
inflammation. Publicly available single cell RNA-sequencing data suggest that AT2 
MHCII expression is undetectable during embryogenesis and increases only after 
birth (Fig 5.2). Thus, it is possible that AT2 MHCII expression is induced and 
sustained by a non-immune environmental stimulus, for example, mechanical stretch 
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or a gaseous component of inhaled air, or is simply an intrinsic part of the AT2 cell 
developmental identity.  
I identified the CIITA pIV isoform as the main transcriptional driver of AT2 
MHCII expression; thus, in future work, I seek to determine the specific transcription 
factors that in turn initiate AT2 CIITA pIV recruitment in AT2s. The three transcription 
factors that have been described to bind to CIITA pIV are STAT1, IRF1, and USF1. 
USF1 is ubiquitously expressed; STAT1 is induced downstream of IFNg and then in 
turn induces expression of IRF1 [58]. However, I demonstrated that AT2 MHCII 
expression is independent of IFNg and STAT1 (Figs 2.4, 2.5). Since IRF1 is induced 
by STAT1, this suggests that AT2 pIV recruitment operates independently of both 
IRF1 and STAT1. Future studies will investigate the requirement of USF1, although it 
seems unlikely that USF1 alone would be sufficient to initiate transcription. Thus, 
future work will also seek to identify other transcription factors and their DNA binding 
 
Figure 5.2: AT2s upregulate MHCII expression after birth. Expression of MHCII a and b chain 
(H2-Aa and H2-Ab1) transcripts measured by single cell RNA-seq in AT2s from mice on the 
embryonic or post-natal days indicated. The results shown here are in whole based upon data 
deposited on the LungMAP Consortium by J. Whitsett, B. Aronow, and S. Potter. They were 
downloaded from (www.lungmap.net), on June 26, 2020. The LungMAP consortium and the 
LungMAP Data Coordinating Center (1U01HL122638) are funded by the National Heart, Lung, 







































sites that mediate CIITA pIV transcription in AT2s. As AT2 MHCII is lost in mice 
lacking an 800bp segment encompassing the CIITA pIV promoter region (STAT1, 
IRF1, and USF1 binding sites), transcription start site (TSS), and first exon [58, 146], 
initial bioinformatics approaches will be used to identify candidate transcription factor 
motifs in this promoter region. However, since this 800 bp deletion does encompass 
the TSS, it is not possible to determine whether the relevant regulatory element is 
contained in this deletion as well. Thus, if initial studies of the DNA elements limited 
to this promoter region are not fruitful, I would expand my search to include the 
possibility of more distal regulatory DNA elements and candidate binding 
transcription factors.   
Once the DNA regulatory elements and transcription factors are identified, it 
will also be of interest to determine whether AT2s share a similar transcriptional 
pathway with TECs and ILC3s, the other two cell types that exhibit IFNg independent 
but CIITA pIV dependent expression of MHCII; the mechanistic drivers of CIITA pIV 
expression in ILC3s and TECs are still not understood. 
 
 
5.4 Polarity of MHCII expression by AT2s  
One aspect of AT2 MHCII expression that warrants further study is the 
surface localization of MHCII. As AT2s are polarized cells, they bear an apical 
membrane that is directed into the alveolar space, and a basolateral surface that 
borders the interstitium. Understanding the localization of MHCII on AT2s will 
provide valuable insight into its function. For example, if MHCII is pointed into the 
interstitium where it would be far more likely to encounter a CD4+ T cell, especially at 
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homeostasis, this would support a stronger function for AT2 MHCII in regulating T 
cell function on a frequent basis. In contrast, if AT2 MHCII is pointed into the alveolar 
space, this would suggest MHCII presentation to CD4+ T cells that is limited primarily 
to situations of substantial inflammation where more T cells infiltrate the alveolar 
spaces. Although I did examine AT2 MHCII expression in situ via 
immunofluorescence microscopy, the techniques I used were not sufficient to 
determine the polarity of AT2 MHCII. Higher resolution imaging studies will be 




5.5 The possibility of novel functions of MHCII on AT2s  
Publicly available bulk RNA-sequencing data of 4 week old mouse AT2s 
demonstrates that invariant chain and MHCII transcripts are some of the most highly 
expressed transcripts in AT2s; in terms of relative abundance, invariant chain (Cd74) 
is #16 and MHCII (H2-Aa) is #32 overall out of more than 20,000 transcripts 
measured (Table 5.1). This observation combined with such high levels of MHCII 
protein on AT2s that appear to be constitutive and inflammation-independent led me 
to wonder whether MHCII serves another key function in the basic biology of AT2s, 
besides interacting with CD4+ T cells.   
To this end, I asked whether MHCII was required for two critical functions of 
AT2s: regenerative capacity and surfactant production. I directly assessed their stem 
cell like function and found that loss of MHCII did not affect their capacity to generate 
organoids in vitro (Fig 3.10). Although surfactant production was not directly 
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assessed, if surfactant biosynthesis or secretion were substantially disrupted, then 
mice lacking MHCII on AT2s would experience severe respiratory failure and 
disease at homeostasis, which I did not observe either clinically or histologically (Fig 
3.9). Thus, MHCII does not appear to be absolutely required for either of these two 
main AT2 functions, but further studies are necessary to determine whether MHCII 
makes a smaller contribution or serves another function in AT2s outside of these 
two.  
 
Rank Gene ID RPKM  Rank Gene ID RPKM 
1 Sftpc 24084.6  19 Rpl41 349.927 
2 Scgb1a1 18103.7  20 Cyp2f2 343.48 
3 Rn45s 5978.34  21 Lamp3 334.136 
4 Lyz2 5809.2  22 Chil1 313.113 
5 Sftpa1 1899.89  23 Scgb3a2 302.334 
6 Cxcl15 1820.24  24 Actb 294.986 
7 Malat1 1711.24  25 Hc 275.855 
8 Sftpb 1325.51  26 Hspa8 275.259 
9 Cbr2 1169.95  27 Eef1a1 263.356 
10 Slc34a2 1114.85  28 Ftl1 263.086 
11 Lars2 981.425  29 Sftpd 260.039 
12 Scd1 936.29  30 Tpt1 242.97 
13 Lyz1 716.109  31 Atp1b1 236.5 
14 Rpl10 447.74  32 H2-Aa 214.948 
15 Tmsb4x 440.907  33 Rps23 210.497 
16 Cd74 438.262  34 S100a11 206.536 
17 Wfdc2 384.277  35 Scgb3a1 203.18 
18 Sod1 382.71  36 S100g 196.786 
 
Table 5.1: MHCII and invariant chain transcripts are among the most highly abundant in 
AT2s. Abundance of the transcripts indicated, measured by bulk RNA-seq, normalized by 
RPKM, in AT2s from naïve 4 week old B6 mice. Highlighted are MHCII (H2-Aa) and invariant 
chain (Cd74) transcripts. The results shown here are in whole based upon data deposited on the 
LungMAP Consortium by J. Whitsett and Y. Xu. They were downloaded from 
(www.lungmap.net), on Nov 18, 2018. The LungMAP consortium and the LungMAP Data 




Another possibility is that MHCII expression is simply a byproduct of its 
coordinated expression with the other CIITA-dependent genes, which instead might 
play the more important role in AT2s at homeostasis. One candidate is invariant 
chain, which has been reported to perform several functions outside of chaperoning 
MHCII [190]. Invariant chain is typically synthesized in molar excess of MHCII and 
thus can reach the cell surface without being associated with MHCII or degraded to 
CLIP peptide; indeed, it is detectable on the surface of AT2s [191]. Previous studies 
have demonstrated that surface invariant chain can serve as a receptor for the 
pleiotropic cytokine MIF-1 [192], and one group has demonstrated this specifically in 
AT2s, suggesting that it may contribute to lung epithelial repair [191]. Globally Cd74-
deficient mice do not exhibit overt lung disease, suggesting that if invariant chain 
does play an alternative role in AT2s, it is not strictly required for their life-sustaining 
functions, similarly to MHCII. 
In general, much more extensive characterization of AT2 function, 
proliferation, survival, gene and protein expression, and more, are needed to 
investigate whether there are other non-immunologic processes that are disrupted 
by the loss of MHCII and or associated genes in AT2s. 
 
 
5.6 The potential role of AT2 MHCII in other immune settings 
I found that the loss of AT2 MHCII resulted in subclinical changes to the 
proportions of naïve, activated, memory, and regulatory phenotype T cells in the 
lungs of aged mice. Specifically, in 14-month-old mice lacking AT2 MHCII, a higher 
proportion of lung CD4+ and CD8+ T cells remained naïve, compared to control mice 
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that had higher proportions of activated, effector memory, and regulatory T cells. As 
discussed in chapter 3, this suggests that AT2 MHCII presentation enhances the 
antigen encounter of lung CD4+ T cells at homeostasis, supporting the formation of a 
variety of antigen-experienced CD4+ and CD8+ T cell subsets.  
The majority of studies of other atypical MHCII+ cells suggest that their MHCII 
expression plays a tolerogenic role at homeostasis. For example, mice lacking 
MHCII on all nonhematopoietic cells [92], or just on ILC3s [90], demonstrate 
increased frequencies of effector memory T cells at homeostasis. Thus, I was 
surprised to find that loss of AT2 MHCII resulted in a decrease in effector memory T 
cells, rather than an increase.  As I observed decreases in both effector memory T 
cells and regulatory T cells in SPCDAb1 mice, this suggests that the role of AT2 MHCII 
at homeostasis is more mixed and may promote both T cell activation as well as 
tolerance and Treg formation depending on the situation.  
The ultimate importance of AT2 MHCII regulation of lung T cells at 
homeostasis is still unclear, given that its impact was small and only apparent in 
aged 14-month-old mice, but not 7-month-old adult mice. Furthermore, the mice did 
not exhibit any signs of lung disease upon loss of AT2 MHCII clinically or when 
measured histologically in 9-month-old mice. It is possible that the contribution of 
AT2 MHCII in vivo at homeostasis to lung T cells is indeed minor and is dispensable 
for a functionally intact lung immune environment. However, it is also possible that 
the homeostatic importance of AT2 MHCII may have been underestimated in our 
experiments, as discussed in chapter 3 and below. 
The fact that loss of AT2 MHCII did not result in overt lung disease at 
homeostasis was surprising for a few reasons. The first is that the constitutive and 
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high levels of MHCII expressed by AT2s, independent of inflammation, strongly 
suggests that AT2 MHCII serves an important function in preventing disease at 
steady state; if only important during inflammation, then presumably AT2s would 
instead behave like all other nonhematopoietic cells and only upregulate MHCII in 
response to IFNg. The second is that homeostatic AT2 MHCII expression in naïve or 
healthy lungs seems to be evolutionarily conserved, at least between rodents and 
human, based on prior reports and our own findings, as demonstrated in chapter 2.  
I also found that MHCII expression by naïve AT2s is conserved across commonly 
used mouse strains C57Bl/6, BALB/c, and C3H (Fig 5.3). Consistent with a prior 
report [105], I did find that AT2s from one mouse strain, A/J, do not express MHCII; I 
will discuss the possible implications of this below. Thirdly, the two cell types that 
have IFNg-independent, CIITA pIV-dependent MHCII induction mechanisms similar 
to AT2s – TECs and ILC3s – play critical roles at homeostasis in central T cell 
development and peripheral selection to prevent immunodeficiency, autoimmunity, 
and pathologic anti-commensal responses. Mice lacking MHCII on ILC3 develop 
spontaneous intestinal disease [90], and the absence of TEC MHCII results in the 
failure of CD4+ T cell positive selection [87], resulting in severe immunodeficiency. 
Thus, I had hypothesized that AT2 MHCII might play an equally critical role at 
homeostasis. Although I did not observe such an overt disease-protecting function 
for AT2 MHCII at homeostasis in our mice housed under SPF conditions, a role may 
be more evident in humans or in wild mice that are exposed to a much larger 
repertoire of inhaled antigens and microbes and have a dramatically different, “less 
naïve” immune system [177, 193-195]; in this setting, the AT2 MHCII-induced 
increase in antigen-experienced lung T cells that I observed could have larger 
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clinical consequences. Furthermore, as discussed in chapter 3, it is also possible 
that in mice of more advanced age, beyond 9 months, histological lung disease may 
become more apparent, even under SPF conditions. 
 I also explored the role of AT2 MHCII in the setting of a primary immune 
response to respiratory viral infection. While loss of MHCII on AT2s did result in an 
increase in disease severity, the impact was modest (Fig 3.11). While the factors 
responsible for this AT2 MHCII protective effective are not yet characterized, the 
most likely mechanism is CD4+ T cell-mediated. Therefore, the moderate clinical 
effect of AT2 MHCII loss that I observed could reflect an equally modest impact on 
the CD4+ T cell response; in prior sections I have suggested that this is due to 
inefficient MHCII antigen presentation by AT2s. However, it could also reflect the fact 
that CD4+ T cells, while critical for optimizing the immune response, are also not 
absolutely required for successful viral clearance or eventual clinical recovery during 
 
Figure 5.3: Homeostatic AT2 MHCII expression is conserved across multiple mouse strains 
but is absent in A/J mice. MHCII protein expression by AT2s from naïve C57Bl/6 (B6) wild-type 
(WT) and MHCII-/- mice, as well as WT BALB/c, A/J, and C3H mice, shown in the colors indicated. 
Expression was measured by flow cytometry using a pan I-A/I-E antibody; the allele that the 
antibody binds to in each strain is listed above each plot. Histograms depict n=2-3 mice per strain. 
Differences in overall MFI between strains are not necessarily reflective of differences in 
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primary influenza or Sendai virus infections in mice [166, 168-171]. Thus, a primary 
influenza or Sendai virus infection model may not be the scenario in which the 
possible contributions of AT2 MHCII would be the most overtly clinically evident or 
immunologically impactful.  Thus, in ongoing and future studies I aim to understand 
the contribution of AT2 MHCII in other disease settings. 
The contribution of primary infection-induced CD4+ T cells is far more evident 
clinically during a subsequent secondary infection. Mice lacking CD4+ T cells during 
a primary infection demonstrate severely impaired B cell responses, limiting the 
development of neutralizing antibodies, and also exhibit poor formation of memory 
CD8+ T cells [162, 163, 171, 196, 197]. Therefore, upon secondary challenge, these 
mice have impaired antibody-mediated protection and inferior capacity to clear the 
virus compared to wild type mice. Thus, a secondary infection challenge model 
would be a clearer way to study the clinical impacts of a potentially impaired CD4 
response generated during primary flu or Sendai virus infection of SPCDAb1 mice.  
I am also interested in understanding whether AT2 MHCII affects the 
development of virus-specific CD4+ memory T cells, as they correlate with 
heterosubtypic protection in humans [198]. Prior studies from the Swain laboratory 
suggest that robust influenza-specific memory CD4+ T cell formation requires two 
cognate TCR-MHCII encounters: the first priming interaction in the lymph node, and 
a second around days 5-7 post-infection [124, 199]. The precise location of this 
second MHCII/antigen encounter is unknown, but as MHCII+ AT2s are present at the 
site of infection where there would be available antigen and antigen-specific CD4+ T 
cells, it is possible that AT2s deliver this second checkpoint and contribute to the 
optimal development of memory CD4+ T cells. It is also possible that local MHCII 
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antigen presentation by AT2s helps to facilitate the development and retention 
specifically of the tissue-resident subset of memory CD4+ T cells (Trm) [200-202]. 
The impact of AT2 MHCII on the development of antigen-specific CD4+ Trm is of 
particular interest, as CD4+ Trm can mediate protection upon viral challenge [203]. 
Other lung disease models in which AT2 MHCII may serve an important 
function are those in which CD4+ T cells play a more direct protective or pathologic 
role. These include models of allergic asthma, in which Th2 phenotype CD4+ T cells 
contribute to airway inflammation directly via the production of the inflammatory 
cytokines IL-4, IL-5, and IL-13 [204]. CD4+ T cells also play a primary role in the 
pathogenesis of lung hypersensitivity pneumonitis, where repeated exposures to 
inhaled organic antigens leads to lymphocytic alveolitis, granulomatous 
inflammation, and progressive lung fibrosis [205-207]. AT2 MHCII could either help 
to protect against these diseases or worsen them. It is possible that AT2 MHCII 
helps to suppress these responses by inducing tolerance of naïve T cells to such 
allergens or environmental antigens; however, it is possible that activation of CD4+ T 
cells by AT2 MHCII antigen presentation contributes to the amplification of this 
immune pathology. It is also possible that AT2 MHCII can perform both of these 
tasks under different circumstances, and a switch in these functions contributes to 
the development of disease. For example, in healthy individuals with no allergy or 
hypersensitivity, AT2 MHCII tolerization of CD4+ T cells operates unperturbed. 
However, in situations of allergy, where inappropriate CD4+ T cell responses have 
been primed and expanded, or in hypersensitivities where large amounts of antigen 
are present in the alveolar spaces, these tolerance mechanisms may be overridden, 
with AT2 MHCII presentation to CD4+ T cells instead resulting in disease. 
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Preliminary data indicates that AT2 MHCII may contribute to protection in the setting 
of ova-induced murine asthma, in that mice lacking MHCII on AT2s exhibit modestly 
higher frequencies of Th2-cytokine producing CD4+ T cells and higher numbers of 
lung eosinophils (Fig 5.4); however, additional studies are needed to corroborate 
this, including those that measure the symptomatic implications of such changes, 
such as airway hyperresponsiveness. 
 Other disease models of interest stem from previous studies of A/J mice; as 
AT2s in A/J mice do not express MHCII, they represent another model in which to 
 
Figure 5.4: SPCDAh1 mice exhibit cellular signs of increased allergic phenotype compared 
to Ab1fl/fl control mice in an inhaled ova allergy model. a-g, Comparison of Ab1fl/fl and SPCDAb1 
mice after ova/alum sensitization followed by intranasal ova challenge. a-c, Numbers of all cells 
(a), eosinophils (b), and T cells (c) in the BAL; n=4-6 mice per strain for Ab1fl/fl and SPCDAb1 mice, 
with n=1 naïve B6 control mouse control. d-g, Proportion of lung CD4+ T cells secreting IL-5 (d), 
IL-13 (e), IL-17 (f), and IFNg (g), after PMA/Ionomycin restimulation; n=6 mice per strain for Ab1fl/fl 
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assess the outcomes of loss of AT2 MHCII. A/J mice are highly susceptible to 
developing spontaneous and carcinogen-induced tumors of AT2 cell origin [208], 
suggesting that the lack of AT2 MHCII may impair cancer-specific immune 
responses in the lung. AT2s also experience particularly severe respiratory virus 
disease compared to other conventional mouse strains [209], and of particular 
interest at this time, they are one of the few strains of inbred mice that are 
susceptible to pulmonary disease after infection with intranasal murine hepatitis 
virus-1 (MHV-1), a mouse betacoronavirus in the same family as SARS-CoV2 [210]. 
As A/J mice also bear other immune-related defects, it is of great interest in future 
work to determine whether the absence of AT2 MHCII directly contributes to worse 
coronavirus disease and more facile cancer development in these mice [211]. 
Finally, it will be an essential avenue of future work will also be to understand 
how our current and future findings in mice translate to human lung immunity. In 
particular, I seek to understand whether alterations in AT2 MHCII expression or 
function contribute to the wide variation in outcome of infectious and immunologic lung 
diseases in humans. Given the current worldwide Covid-19 pandemic, I am also 
particularly interested in whether AT2 MHCII contributes to protection or to the 
outcome of disease in the setting of SARS-CoV-2 infection; as AT2s are the main cell 
type infected with this virus in the human lung parenchyma [212-214], they may 
contribute to SARS-CoV-2 specific CD4+ T cell responses via endogenous MHCII 




5.7 Concluding remarks: why do AT2s express MHCII? 
A central question underlying this work is, teleologically, why would AT2s 
“need” to express MHCII? Or framed another way, given the expansive and intricate 
network of conventional immune cells and specialized immune organs that comprise 
the formal immune system, why would the lower respiratory tract have evolved to 
also have its own parenchymal cells constitutively express MHCII?  
The most straightforward explanation is that this provides an additional 
mechanism to further tailor the adaptive immune response based on the structural 
and functional constraints of the lung. The respiratory tract is a barrier site, and thus 
is constantly faced with both innocuous and potentially harmful insults. It is also a 
location where having excessive cellular infiltration and inflammation is particularly 
dangerous and often has lethal consequences. As most immune cells, in particular T 
cells, are circulatory, they migrate throughout various organs to exert their effector 
functions without necessarily intrinsically discriminating based on anatomic location 
per se. Having a local and lung-specific MHCII-expressing cell that is specifically 
adapted to regulate these responses, to facilitate rapid infection resolution but spare 
the delicate gas-exchange surface, would be enormously beneficial. AT2s are highly 
abundant in the lung parenchyma, and they are poised anatomically at the air/tissue 
interface, making them uniquely situated to respond to foreign substances that reach 
the alveolar spaces. Furthermore, they are replete with their own specialized set of 
intracellular machinery, and they are preferentially infected by a variety of 
pathogens, endowing them with unique antigen processing and presentation 
characteristics in comparison to conventional APCs. Thus, AT2s are prime 
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candidates for contributing to this crucial tissue-specific immune regulation in the 
lung via MHCII. 
Over the last decade or so, the study of immunology in peripheral tissues, 
rather than in the blood and secondary lymphoid organs, has become more 
commonplace. Furthermore, the importance of contributions made by stromal and 
parenchymal cells to shape these immune responses based on organ-specific 
considerations has been increasingly appreciated [215, 216]. Here I propose that 
AT2 cells, by virtue of their constitutive MHCII expression and restrained MHCII 
antigen presentation, contribute to the regulation of local immune responses in the 
lung. It is our hope that future studies will build upon our initial findings to elucidate 
roles for AT2 MHCII antigen presentation in other situations of homeostasis and 
disease, adding to our basic understanding of the exquisite complexities of how 




CHAPTER 6:  
MATERIALS AND METHODS  
 
Mice 
C57Bl/6 wild-type (B6), B6.129S2-H2dlAb1-Ea/J (MHCII-/-) [217], B6;129S4-H2-
DMatm1Luc/J (H2-DMa-/-) [29], B6.129S7-Ifngtm1Ts/J (Ifng-/-) [218], B6.129S(Cg)-
Stat1tm1Dlv/J (Stat1-/-) [219], C.129S2(B6)-Ciitatm1Ccum/J (Ciita-/-) [54, 220], B6.SJL-
Ptprca Pepcb/BoyJ (CD45.1 B6), B6.129X1-H2-Ab1tm1Koni/J (H2-Ab1fl/fl) [158], as well 
as C3H, A/J, BALB/c, and CB6F1/J (F1 [BALB/c x C57Bl/6] mice were originally 
purchased from the Jackson Laboratory. C57Bl/6 Cd74-/- mice [20] were originally 
provided by Guo-Ping Shi (Harvard), and C57Bl/6 Ciita pIV-/- mice [146] were provided 
by S. Hugues (University of Geneva).  C57Bl/6 SPC-Cre-ERT2 mice [157] were 
provided by G.S. Worthen, B6.129S7-Ifngr1tm1Agt/J (Ifngr1-/-) [221], B6(Cg)-
Ifnar1tm1.2Ees/J (Ifnar1-/-) [222], and B6.Cg-Ifngr1tm1Agt Ifnar1tm1.2Ees/J (Ifnar1-/-Ifngr1-/-) 
mice were provided by E. Behrens, and germ-free mice were provided by M. Silverman 
(Children’s Hospital of Philadelphia). C57Bl/6 B6.129P2(SJL)-Myd88tm1.1Defr/J (Myd88-
/-) mice [223] were provided by S. Shin, and B6.129S2(C)-Stat6tm1Gru/J (Stat6-/-) mice 
[224] were provided by C. Hunter (University of Pennsylvania). All mice were 
maintained in specific pathogen-free facilities at the Children’s Hospital of 
Philadelphia, except for Myd88-/- and Stat6-/- mice, which were housed in specific 
pathogen-free facilities at the University of Pennsylvania, and germ-free mice, which 
were housed in gnotobiotic mouse facilities at the University of Pennsylvania. Mice 
were age and sex matched for all studies. 8-12 week old mice were used for all 
experiments except where indicated in the text.  All animal procedures were in 
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compliance with institutional and AAALAC ethical guidelines and were approved by 




The B6 primary skin fibroblast cell line was derived in our laboratory and has 
been described previously [225]; it was maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 5% FBS, Penicillin-Streptomycin, and 2mM L-glutamine. 
Madin-Darby canine kidney (MDCK) cells were provided by S. Hensley (University of 
Pennsylvania) and were maintained in MEM with 10% FBS. Monkey kidney LLC-MK2 
cells were provided by Carolina Lopez (University of Pennsylvania) and were 
maintained in DMEM with 10% heat-inactivated FBS, Penicillin-Streptomycin, 2 mM 
L-glutamine, and 1 mM sodium pyruvate. T cell hybridoma lines were derived in our 
laboratory and have been described previously [46, 178]; these were maintained in 
“complete RPMI” media: RPMI media containing 10% FBS, 50 µM 2-mercaptoethanol, 
Penicillin-Streptomycin, 2mM L-glutamine. 
 
Viruses 
Mouse lung-adapted H1N1 influenza A virus, A/Puerto Rico/8/1934 (IAV PR8), 
was originally provided by C. Lopez (University of Pennsylvania), and then expanded 
in 10-day-old embryonated chicken eggs. IAV PR8 viral titer was determined by 
standard focus-forming unit (FFU) assay in MDCK cells.  Sendai virus, strain 52 (SeV 
52), was also a generous gift of C. Lopez (University of Pennsylvania). SeV 52 viral 
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titer was determined using a tissue culture infectious dose (TCID50) standard infectivity 
assay in LLC-MK2 cells. 
 
Synthetic peptides 
The following synthetic peptides were used: HA91-107 
(RSWSYIVETPNSENGIC), NA161-175 (SVAWSASACHDGMGW), HA302-313 
(CPKYVRSAKLRM), HA107-119 (SVSSFERFEIFPK), NA79-93 (IRGWAIYSKDNSIRI). All 
peptides were obtained at >85% purity from Genscript. 
 
Tissue isolation for in vitro analysis and flow cytometry 
For isolation of AT2 cells, the lung vasculature was first perfused with 5 mL 
PBS by injecting into the cardiac right ventricle. Lungs were then inflated via 
intratracheal instillation of 0.9 mL AT2 digest media [5 U/mL Dispase (354235, 
Corning), 1.66 mg/mL Collagenase A (10103586001, Sigma), 0.33 mg/mL DNase I 
(10104159001, Sigma) in PBS]. The trachea was then tied with suture to keep the 
lungs inflated while they were excised en bloc and then placed in an additional 1 mL 
digest media, then incubated at 37°C. After 45 minutes, 5 mL 20% FBS in PBS was 
added, and the parenchymal lung lobes were removed from the large airways with 
forceps, then dissociated by vigorous pipetting. Digested lungs were passed through 
a 70 µm strainer, incubated in ACK lysis buffer to remove RBCs, then passed through 
a 40 µm strainer to obtain a single cell suspension. 
For isolation of lung T cells, the lung vasculature was first perfused with 5 mL 
1% FBS in PBS by injecting into the cardiac right ventricle. Individual parenchymal 
lung lobes were removed from the chest cavity and placed into gentleMACS C tubes 
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containing 2 mL 1% FBS in PBS.  Lymphocyte digest media was then added to the 
lungs (1% FBS, 2.25 mg/mL Collagenase D (11088866001, Sigma), 0.15 mg/mL 
DNase I in PBS in 4 mL final volume), which were then gently disrupted using 
gentleMACS homogenizer program m_spleen_01.01, then incubated for 45 minutes 
at 37C with shaking.  Complete RPMI media was then added to each tube, followed 
by further dissociation using gentleMACS homogenizer program m_lung_02.01. 
Digested lungs were then passed through a 70 µm strainer, incubated in ACK lysis 
buffer to remove RBCs, then passed through a 40 µm strainer to obtain a single cell 
suspension. 
AT2s could not be recovered from the T cell digest; likewise, the AT2 digest 
was not optimal for T cell isolation as it resulted in the degradation of surface CD4 and 
CD8 from T cells. In some T cell isolation experiments, a small sample of AT2s was 
also needed for the purposes of confirmation phenotyping to assess deletion or 
presence of MHCII. In these cases, prior to the addition of lymphocyte digest media 
to the lungs, a small ([<2mm]3) portion of lung was removed, and then incubated for 1 
hour at 37C in 0.4 mL AT2 digest media. Next, 0.1 mL of FBS was added, and the 
sample was then homogenized through a 40 µm cell strainer using the flat end of a 1 
mL syringe plunger, to obtain a single cell suspension. 
To harvest lungs for virus titering, lung lobes were removed directly from the 
thoracic cavity (with no perfusion or instillation) and placed in gentleMACS M tubes 
containing 1 mL PBS.  Additional PBS was then added to each M tube to produce a 
final 10% weight/volume solution of lungs/PBS. Lungs were then homogenized using 
gentleMACS dissociator program RNA_01.01. Cellular debris was removed by 
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centrifugation at 600xg for 10” at 4°C, and the clarified supernatant was then used for 
virus titering. 
For isolation of splenocytes, spleens were removed from the abdominal cavity 
and placed directly in PBS. Spleens were then homogenized through a 70 µm cell 
strainer using the blunt end of a 3 mL syringe plunger. The splenocytes were then 
incubated in ACK lysis buffer to remove RBCs, then passed through a 40 µm strainer 
to obtain a single cell suspension. 
For isolation of immune cells from peripheral blood, blood was collected via 
cheek bleed or IVC puncture into PBS containing 25 mM EDTA. Samples were 
centrifuged at 300xg for 10”, followed by ACK lysis of the cell pellet to remove RBCs. 
For isolation of bone marrow cells, whole bones of the hindlimb were removed 
from mice. In a sterile manner, the ends of the bones were cut and the interior cavity 
was flushed with PBS. 
For isolation of BAL cells, the trachea was cannulated and flushed three times 
with 0.7 mL of PBS containing 5% BSA, 2 mM EDTA, and complete Mini, EDTA-free 
protease inhibitor cocktail (11873580001, Sigma). Each flush was collected separately 
and kept on ice, then centrifuged at 6800xg at 4°C for 2 minutes. The supernatant was 
removed and the cell pellets from all three flushes were combined, then incubated in 
ACK lysis buffer to remove RBCs. 
For isolation of human distal lung cells, healthy human lungs were obtained 
with informed consent from the Prospective Registry of Outcomes in Patients Electing 
Lung Transplant Study approved by University of Pennsylvania Institutional Review 
Board in accordance with institutional ethical procedures and guidelines. The donor 
used in this study had the following characteristics: 36 y.o. M, no smoking history, no 
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evidence of active infection, P/F ratio of 346. Lungs were digested as described 
previously by Zacharias and Morrisey [226]. Briefly, a 2x2 cm piece of distal lung tissue 
(pleura and airways removed) was minced then processed in the same AT2 digest 
media as above using a gentleMACS dissociator at 37°C for 35 minutes. Digested 
lungs were washed, passed through 70 µm and 40 µm strainers, and then incubated 
in ACK lysis buffer to remove RBCs and generate a single cell suspension.  
 
Cell type identification via flow cytometry and cell sorting 
All flow cytometry antibodies used are listed in Table 6.1. For all flow cytometry 
experiments, unless otherwise stated, single cell suspensions were first stained for 
dead-cell exclusion with Live/Dead Aqua (L34957, Thermo Fisher) in PBS, followed 
by Fc-receptor blockade with anti-CD16/CD32 (553141, BD) for mouse cells or Human 
TruStain FcX (422301, Biolegend) for human cells,  in 0.1% BSA in PBS. Cells were 
then stained with surface antibodies diluted in 0.1% BSA in PBS for 30” in the dark at 
4°C. If necessary, cells were then fixed and permeabilized for intracellular staining 
using the BD Cytofix/Cytoperm kit (554714, BD) or for intranuclear staining using the 
eBioscience Foxp3/Transcription Factor Staining kit (00-5523-00, Thermo Fisher). 
Intracellular and intranuclear stains were diluted in the corresponding kit wash buffer 
and were incubated for 30” at room temperature. Flow cytometry data were acquired 
on the following analyzers: LSRII and LSRFortessa (BD), CytoFLEX LX and 
CytoFLEX S (Beckman Coulter). Cell sorting was performed on the following sorters: 
FACSAria Fusion and FACSJazz (BD), and MoFlo Astrios (Beckman Coulter). All flow 
cytometry analyses were conducted using FlowJo software (FlowJo LLC). 
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Murine AT2s were identified by flow cytometry as detailed in Fig 6.1 [105]. In 
studies where MHCII expression was evaluated, AT2s were identified using the gating 
strategy without MHCII as a selection marker, as CD45-, CD31-, EpCAMint cells (Fig 
6.1b). For all other flow cytometry studies, AT2s were identified as CD45-, CD31-, 
EpCAM+ MHCII+ cells (Fig 6.1a). Both gating strategies were validating by intracellular 
staining for pro-SPC (Fig 6.1c). Human AT2s were identified by flow cytometry as 
detailed in Fig 6.2 as HT2-280+ lung cells [145], by staining with unlabeled anti-HT2-
280 followed by an anti-mouse IgM fluorophore-conjugated secondary antibody. 
Other cell types were identified via flow cytometry as follows:  Lung endothelial 
cells (CD45-, CD31+), Lung CD103+ DCs (CD45+, CD11c+, CD103+), Lung alveolar 
macrophages (CD45+, CD11c+, CD103-, CD11b-, CD64+), Splenic CD8+ DCs (CD45+, 
CD11c+, CD3-, CD8+), B cells (FSC-Alow, CD45+, CD11c-, CD19+ or B220+), T cells 
(CD45+ CD3+), CD4+ T cells (CD45+, CD3+, CD4+, CD8-), CD8+ T cells (CD45+, CD3+, 
CD8+, CD4-),  NK cells (CD45+, CD3-, NK1.1+), gd T cells (CD45+, CD3+, TCRd+), 
neutrophils (CD45+, CD11c-, CD11b+, Ly6G+), and eosinophils (CD45+, CD11c-, 
CD11b+, Ly6G-, SiglecF+).  
For cell sorting experiments, samples were not stained with the Live/Dead 
viability dye or Fc-receptor blockade to minimize sample processing time and preserve 
cell viability. The following professional APC populations were sorted: qPCR DCs 
(CD45+,CD11c+,MHCIIhi); DQ-ova assay DCs (CD45+, CD11c+, MHCIIhi) and B cells 
(CD45+, B220+, MHCII+); C57Bl/6 hybridoma assay CD11c+/CD19+ APCs (CD45+, 
MHCII+, CD11c+ or CD19+); Balb/c hybridoma assay CD11c+ APCs (CD45+, MHCII+, 
CD11c+); ELISpot CD103+ DCs (CD45+, CD11c+, CD103+). The following AT2 
populations were sorted: DQ-ova assay, qPCR, C57Bl/6 hybridoma assay and Balb/c 
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hybridoma assay AT2s (CD45-, CD31-, EpCAM+, MHCII+), ELISpot AT2s (CD45-, 
CD31-, EpCAM+), and AT2s for organoid culture (CD45-, CD31-, Podoplanin-, CD34-, 




Figure 6.1: Murine AT2s gating strategies. a,b, Flow cytometry gating strategy for murine AT2s 
using MHCII as a positive marker (a) or without using MHCII as a positive marker (b). The right 
column contour plots are the same as the final pseudocolor plots in the corresponding gating 
strategies, and they are shown to highlight the final AT2 population defined from each strategy. c, 
Comparison of the two populations of AT2s identified by the two gating strategies in terms of 
MHCII expression (contour plot, left) or pro-SPC expression (histogram, right). 
 
 
Figure 6.2: Human AT2s gating strategy. Flow cytometry gating strategy for human AT2s. The 
right-most contour plot highlights in blue the final AT2 population defined by HT2-280+ staining. 
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 Flow cytometric detection of MHCII, peptide/MHCII complexes, and associated 
machinery 
To assess total surface MHCII expression in wild-type and knockout mice, cells 
were stained with a pan I-A/I-E anti-MHCII antibody. Human MHCII was detected 
using an anti-HLA-DR antibody. For detection of specific MHCII alleles in YAe 
presentation assays, cells were surface stained with anti-I-Ab and anti-I-Ed antibodies. 
Mouse invariant chain and H2M expression were detected by staining intracellularly 
with anti-mouse CD74 and anti-H2Mab2 antibodies, respectively.  Two different 
fluorophore-conjugated versions of the anti-H2Mab2 antibody were labeled in house, 
with the Pacific Blue and Alexa Fluor 647 labeling kits (P30013 or A20186, Thermo 
Fisher).  Human invariant chain was detected using an anti-human CD74 antibody, 
and HLA-DM was detected using an anti-HLA-DM antibody [227] provided by L. 
Denzin (Rutgers). CLIP-loaded MHCII molecules were detected on the cell surface by 
using an CLIP/I-Ab complex specific antibody [227] provided by L. Denzin (Rutgers). 
To detect Ea52-68/I-Ab complexes, lung cells were surface stained with a biotinylated 
Y-Ae antibody followed by APC-Streptavidin (405207, Biolegend). 
 
Costimulatory molecule expression analysis 
To generate bone marrow-derived dendritic cells (BMDCs), bone marrow cells 
were grown in complete RPMI media supplemented with 20 ng/mL mouse 
recombinant granulocyte-macrophage colony-stimulating factor (“GM-CSF”; 10822-
026, Shenandoah Biotechnology). Fresh media was added on days 3 and 6 after 
plating, and the floating fraction of cells was harvested on day 7-10. 
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Mice were infected intranasally with 60 FFU IAV PR8 diluted in 20 µL PBS 
under isoflurane anesthesia. Lungs were harvested from mice 5 days after infection 
or from naïve mice. 
To evaluate the expression of costimulatory molecules, BMDCs, bulk 
splenocytes, and lung cells were surface stained with anti-CD80, anti-CD86, and anti-
CD54 (ICAM1) antibodies. 
 
DQ-ovalbumin assay 
0.75-1.25x105 AT2s, DCs, and B cells were incubated with either 0 or 10 µg/mL 
DQ-ovalbumin (D12053, Thermo Fisher) in complete RPMI media at either 37°C or 
4°C for 2 hours. Cells were then washed 3x with PBS and stained with Live/Dead 
Aqua; cells were maintained at 4°C during these steps. Fluorescence was then 
immediately assessed by flow cytometry. 
 
RNA isolation and quantitative PCR 
Total RNA was extracted and purified using the Qiaqen RNeasy Plus Mini Kit 
(74134, Qiagen), and cDNA was then prepared using the SuperScript III First-Strand 
Synthesis System with random hexamers (18080051, Thermo Fisher). Quantitative 
PCR was performed using the Power SYBR Green PCR Master Mix system (4367659, 
Thermo Fisher) measured using a StepOnePlus Real Time PCR Machine (Applied 
Biosystems). Expression was quantified relative to the housekeeping gene Hprt using 
the DCT method. The following forward (F) and reverse (R) primer pairs were used. 
H2-Aa F: CTGATTCTGGGGGTCCTCGC and R: CCTACGTGGTCGGCCTCAAT;  
H2-Ab1 F: GAGCAAGATGTTGAGCGGCA and R: 
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GCCTCGAGGTCCTTTCTGACTC; H2-DMa F: GGCGGTGCTCGAAGCA and R: 
TGTGCCGGAATGTGTGGTT; H2-DMb1 F: CTATCCAGCGGATGTGACCAT and R: 
TGGGCTGAGCCGTCTTCT; Hprt F: TCAGTCAACGGGGGACATAA and R: 
GGGGCTGTACTGCTTAACCAG. 
 
Bone marrow chimeras 
Donor bone marrow was isolated from C57Bl6 MHCII-/- and CD45.1 B6 mice, 
and T cells were depleted magnetically using Thy1.2 Dynabeads (11443D, Thermo 
Fisher).   5x106 bone marrow cells were then injected intravenously into lethally 
irradiated recipient C57Bl6 MHCII-/- and CD45.1 B6 mice 6 hours after irradiation was 
completed (5.5 Gy x 2 doses, 3 hours apart). Mice were treated with Bactrim for 3 
weeks following the transfer and were housed in autoclaved cages. 
Full bone marrow chimera reconstitution was confirmed 6 weeks after transfer, 
by flow cytometry analysis of peripheral blood cells stained with anti-CD45.1 and anti-
CD45.2 antibodies.  MHCII expression on chimeric mouse lung cells was assessed 8 
weeks post-transfer. 
 
Detection of germline MHCII deletion 
Consistent with prior reports [228, 229], our Ab1fl/fl mice experienced 
spontaneous germline disruption of the I-Ab locus at a rate of ~5%, resulting in global 
loss of MHCII from all cells. Therefore, in addition to standard genotyping all SPCDAb1 
and Ab1fl/fl mice were screened at >5 weeks of age for germline deletion of MHCII, by 
flow cytometric measurement of MHCII on peripheral blood immune cells isolated by 
cheek bleed. Specifically, cells were stained for surface expression of CD45, CD19, 
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and MHCII, and mice were excluded from further study if B cells (CD45+ CD19+) lacked 
MHCII expression. All mice included in experiments discussed here had appropriately 
intact MHCII expression by peripheral blood screening. 
 
Tamoxifen administration 
SPCDAb1, Ab1fl/fl, and SPCCre mice >5 weeks of age were oral gavaged daily 
with 2 mg tamoxifen for 4 days, by delivering 100 µL of 20 mg/mL solution of tamoxifen 
(T5648, Sigma) in a 9:1 corn oil:ethanol mixture. Mice were used in experiments ³5 
days after the last dose of tamoxifen. 
 
Histological analysis 
To assess MHCII expression in SPCDAb1, Ab1fl/fl, and MHCII-/- mice by 
immunofluorescence, the lung vasculature was first perfused with 5 mL 4% 
paraformaldehyde in PBS (4% PFA) by injecting into the cardiac right ventricle. Lungs 
were then inflated via intratracheal instillation of 0.9 mL 4% PFA. The trachea was 
then tied with suture to keep the lungs inflated while they were excised en bloc and 
then placed in an additional 30 mL 4% PFA, then incubated for 24 hours at 4°C. Tissue 
was then processed, paraffin-embedded, sectioned, and stained with DAPI, and the 
following antibodies: anti-mouse pro-SPC (AB3786, EMD Millipore), anti-mouse 
MHCII (107601, Biolegend), and anti-mouse E-cadherin (ab76319, Abcam). Images 
were acquired using an Axio Observer 7 widefield microscope with Axiocam 702 
monochrome CMOS camera and Zen blue acquisition software (Zeiss). Composite 
images were then generated in Fiji. 
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To assess lung pathology at homeostasis in SPCDAb1 and Ab1fl/fl mice, the lungs 
were inflated via intratracheal instillation of ~1 mL 10% neutral buffered formalin 
(NBF), then placed in an additional ~30 mL 10% NBF and incubated for 24 hours at 
RT. Tissue was then processed, paraffin-embedded, sectioned, and stained with 
hematoxylin and eosin, and the resulting lung sections were evaluated for signs of 
disease by a veterinary pathologist. Images were acquired using an Axio Observer 7 
widefield microscope with Axiocam 503 color CCD camera and Zen blue acquisition 
software (Zeiss).  
 
T cell phenotyping analyses 
For determination of T cell phenotype as well as activation status, cells were 
surface stained for the following markers: CD44, CD62L, CD69, CD11a, PD1, and 
LAG3. Cells were also stained intranuclearly for FoxP3 and Ki67. 
 
Lung organoids 
Alveolar organoids were cultured as described previously [115, 143], with the 
following modifications. Briefly, 5x103 AT2s sorted from either SPCDAb1 and Ab1fl/fl mice 
were cocultured with 5x104 Pdgfra+ lung fibroblasts sorted from WT C57Bl/6 mice. 
Cells were suspended in 90µL of a 1:1 mixture of Matrigel:modified SAGM media (CC-
3118, Lonza). SAGM media is modified by adding 0.1 µg/mL cholera toxin (C8052, 
Sigma) and the following SAGM BulletKit components: 10 µg/mL insulin, 5 µg/mL 
transferrin, 25 ng/mL EGF, 30 µg/mL bovine pituitary extract, 0.01µM retinoic acid, 
and 5% FBS.  The 1:1 mixture containing cells was placed in a cell culture insert 
(353095, Corning); after solidification of the matrix at 37°C, the insert was placed 
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inside a well of 24-well plate containing modified SAGM media. For the first two days 
of culture, 10 µM ROCK inhibitor Y27632 (Y0503, Sigma) was added to the media. 
The media was changed every 48 hours, and after 21 days organoids were imaged 
using an EVOS FL Auto. Organoid numbers were quantified in Fiji using the Cell 
Counter plugin. 
 
Virus infections for weight loss and mortality analysis 
For influenza infection weight loss monitoring, mice were infected intranasally 
with 3 FFU IAV PR8 diluted in 20 µL PBS under isoflurane anesthesia. For influenza 
infection mortality experiments, mice were infected intranasally with 15 FFU IAV PR8 
diluted in 20 µL PBS under isoflurane anesthesia. For both Sendai virus infection 
weight loss monitoring and mortality analyses, mice were infected intranasally with 
3.5-7x104 TCID50 SeV 52 diluted in 35 µL PBS under ketamine (70 mg/kg) + xylazine 
(5 mg/kg) anesthesia. For all weight loss experiments, mice were weighed on the days 
indicated. For all mortality studies, mice were monitored daily for death or moribund 
state as an endpoint. 
 
Lung virus titering 
For influenza virus titering, mice were infected intranasally with 3 FFU IAV PR8 
diluted in 35 µL PBS under ketamine (70 mg/kg) + xylazine (5 mg/kg) anesthesia. For 
Sendai virus titering, mice were infected intranasally with 7x104 TCID50 SeV 52 diluted 
in 35 µL PBS under ketamine (70 mg/kg) + xylazine (5 mg/kg) anesthesia. Mice were 
sacrificed at the timepoints indicated for virus titers analysis. 
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For influenza virus titers determination, MDCK cells were infected with serial 
10-fold dilutions of lung homogenates in MEM containing 50µg/mL gentamicin, 5mM 
HEPES, and 1µg/mLTPCK-treated trypsin (LS003750, Worthington Biochemical) in 
quadruplicate per lung. After 4 days of incubation at 37°C, the presence of virus at 
each dilution was determined by visual cytopathic effect, and lung virus titers were 
determined using the Reed and Muench Calculation. 
For Sendai virus titers determination, LLC-MK2 cells were infected with serial 
10-fold dilutions of lung homogenates in DMEM containing 50µg/mL gentamicin, 
0.35% BSA, 0.12% NaHCO3, and 2 µg/mL TPCK-treated trypsin in triplicate per lung. 
After 3 days of incubation at 37°C, the presence of virus was determined by assessing 
the capacity of 25µL of supernatant at each dilution to hemagglutinate 0.25% chicken 
red blood cells (cRBCs) in a 100µL final volume after a 30” incubation at room 
temperature. Lung virus titers were then determined using the Reed and Muench 
Calculation. 
 
Influenza LAG3+ T cell expansion analysis 
Mice were infected intranasally with 3 FFU IAV PR8 diluted in 20 µL PBS under 
isoflurane anesthesia. Mice were sacrificed 9 days after infection and lungs were 
stained ex vivo for T cell surface markers and LAG3. 
 
Hybridoma assay 
NFAT-lacZ-inducible T cell hybridomas recognizing MHCII-restricted influenza-
derived epitopes have been described previously [46, 178]. Hybridoma recognition of 
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cognate peptide/MHCII complexes results in b-galactosidase production, which was 
detected using a fluorometric β-galactosidase substrate 4-methyl-umbelliferyl-β-D-
galactopyranoside (“MUG”; M1633, Sigma). 
1x104 APCs were treated with media only, 20 µg/mL peptide, or 1x106 FFU 
influenza virus in complete RPMI media for 45” at 37°C, 6% CO2 in a 384 well plate; 
for AT2 conditions, wells were pre-coated with a thin layer of 9:1 RPMI:Matrigel 
(356231, Corning) mixture. After 45”, 2x104 hybridomas were directly added, and cells 
were then cocultured for 14-18 hours at 37°C, 6% CO2. MUG substrate solution (33 
µg/mL MUG in PBS containing 38.5 µM 2-mercaptoethanol, 9 mM MgCl2, and 1.25% 
NP40) was then added to the co-culture at a ratio of 1:5 MUG solution:co-culture, then 
incubated for 3 hours at 37°C, 6% CO2. Fluorescence (excitation: 365 nm, emission: 
445nm) was detected on Tecan Infinite M200 Pro Plate Reader. 
 
IFNg ELISpot assay 
For isolation of influenza-infected APCs, WT and MHCII-/- mice were infected 
intranasally with 1.2x106 FFU IAV PR8 diluted in 35 µL PBS under ketamine (70 
mg/kg) + xylazine (5 mg/kg) anesthesia. Lungs were harvested from mice 4 days after 
infection or from naïve mice. APCs were isolated via cell sorting, as above. 
For isolation of influenza-experienced effector T cells, WT mice were infected 
intranasally with 3 FFU IAV PR8 diluted in 35 µL PBS under ketamine (70 mg/kg) + 
xylazine (5 mg/kg) anesthesia. Spleens were harvested from mice 10 days after 
infection.  CD4+ and CD8+ T cells were isolated from bulk splenocytes using 
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Dynabeads Untouched Kits for mouse CD4 cells and CD8 cells, respectively, per the 
manufacturer’s protocol (11415D and 11417D, Thermo Fisher). 
96-well MultiScreenHTS IP 0.45 µm filter plates (MSIPS4W10, Millipore-Sigma) 
were coated with mouse IFNg capture antibody (551881, BD) and incubated at 4°C for 
20 hours prior to the assay. Plates were blocked with complete RPMI media for >1 
hour at 37°C, after which 5x104 APCs and 1x105 T cells were co-cultured for 14-18 
hours in the presence of 2µg/mL anti-CD28 (40-0281-M001, Tonbo Biosciences).  T 
cell IFNg production was detected via biotinylated IFNg detection antibody (551881, 
BD), followed by HRP-Streptavidin (557630, BD) and chromogenic 3-Amino-9-
ethylcarbazole (AEC) substrate (551951). IFNg spots were imaged and counted using 
a CTL ImmunoSpot S6 Universal Analyzer. 
 
Detection of influenza-infected cells 
For quantification of influenza virus infection in hybridoma and ELISpot assays, 
at assay endpoint cells were stained for surface hemagglutinin (HA) protein 
expression or intracellular nucleoprotein (NP) protein expression.  Two different 
fluorophore-conjugated versions of the anti-HA antibody were labeled in house, with 
the Alexa Fluor 488 and Alexa Fluor 647 labeling kits (A20181 or A20186, Thermo 
Fisher). 
 
IFNg treatment of mice 
Mice were injected intravenously under isoflurane anesthesia once daily with 
1x105 U recombinant mouse IFNg (575306, Biolegend) in 150 µL PBS, or PBS only, 
for 3 days in a row. 
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Inhaled Ova allergy model 
Mice were injected intraperitoneally with 10µg ova (A5503, Sigma) and 2.25mg 
Alum (77161, Thermo Fisher) in 200µL on days 0 and 14. 10µg ova protein in 20µL 
PBS was then administered to mice intranasally under isoflurane anesthesia once 
daily on days 28, 29, and 30. BAL cells and lung T cells were harvested on day 31, as 
described above. 
 
Intracellular cytokine staining 
For intracellular cytokine staining, lung cells from ova-immunized mice were 
incubated in R10 media containing 2µg/mL anti-CD28, 50 ng/mL phorbol 12-myristate 
13-acetate (PMA), 1µg/mL ionomycin, and 1X brefeldin-A (420601; Biolegend) for 5 
hours at 37°C. Cells were then surface stained with anti-mouse CD8, and 
intracellularly with antibodies against mouse CD3, CD4, IL5, IL13, IL17, and IFNg. 
 
Analysis of publicly available RNA-sequencing data 
For analysis of H2Mb1 and H2Mb2 expression by B cell, dendritic cell, and 
macrophage subsets, bulk RNA-sequencing data was obtained using the 
Immunological Genome Project [153] Gene Skyline RNA-seq Data Browser, available 
at (http://rstats.immgen.org/Skyline/skyline.html).  
For analysis of AT2 cells by bulk RNA-sequencing and single cell RNA-
sequencing, data were obtained from the LungMAP consortium, which is funded by 
1U01HL122638. The bulk RNA-sequencing dataset was contributed by Jeffrey A. 




ties). The single cell RNA-sequencing dataset was contributed by Jeffrey A. Whitsett 







All statistical analyses were performed using Prism 8 software (GraphPad). 
The statistical tests used are indicated in the figure legend corresponding to each 
specific experiment. Unpaired two-tailed Student’s t-test was used to compare means 
between two groups if they had similar variances by F-test, and if they passed all four 
of the following normality of residuals tests: Anderson-Darling, D’Agostino-Pearson 
omnibus, Shapiro-Wilk, and Kolmogorov-Smirnov. If variances were significantly 
different, unpaired two-tailed Welch’s t-test was used, and if the samples failed at least 
one normality test then two-tailed Mann-Whitney test was used. For weight loss 
analysis, a mixed model, which uses a compound symmetry covariance matrix and is 
fit using Restricted Maximum Likelihood (REML), with Geisser-Greenhouse correction 
was used, followed by post-hoc multiple comparisons with Sidak’s correction; this was 
used instead of repeated-measures ANOVA, as it can handle missing values. For 
mortality analysis, the Log-rank (Mantel-cox) test was used to compare survival 
curves. Two-way ANOVA followed by post-hoc multiple comparisons with Tukey’s or 
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Sidak’s correction was used to compare means between groups with 2 contributing 
independent variables; Tukey’s correction was used when all possible means were 
compared, and Sidak’s correction was used when means were compared across one 
factor only. Three-way ANOVA followed by post-hoc multiple comparisons with 




 Flow cytometry antibodies used 
Target Clone or Catalog # Source 
mouse CD45 30-F11 Biolegend 
mouse CD31 390 Biolegend 
mouse EpCAM (CD326) G8.8 Biolegend 
mouse I-A/I-E (MHCII) M5/114.15.2 Biolegend 
mouse proSP-C AB3786 Sigma Aldrich 
human HT2-280 TB-27AHT2-280 Terrace Biotech 
mouse IgM II/41 Thermo Fisher 
mouse CD11c N418 Biolegend 
mouse CD103 2E7 Biolegend 
mouse CD11b M1/70 BD 
mouse CD64 X54-5/7.1 Biolegend 
mouse CD3 145-2C11 or 17A2 BD or Biolegend 
mouse CD8 53-6.7 BD 
mouse CD19 6D5 Biolegend 
mouse B220 RA3-6B2 Biolegend 
mouse CD4 RM4-5 or GK1.5 Biolegend 
mouse NK1.1 PK136 Thermo Fisher 
mouse TCRd GL3 Biolegend 
mouse Ly6G 1A8 BD 
mouse SiglecF E50-2440 BD 
mouse Podoplanin 8.1.1 Thermo Fisher or Biolegend 
mouse Sca-1 D7 Thermo Fisher 
mouse CD34 MEC14.7 Biolegend 
mouse Pdgfra (CD140a) APA5 Thermo Fisher 
human HLA-DR G46-6 BD 
mouse I-Ab AF-120.1 Thermo Fisher 
mouse I-Ed 14-4-4S Biolegend 
mouse invariant chain (CD74) In-1 BD 
mouse H2Mab2 2E5A BD 
human invariant chain (CD74) Pin.1 Biolegend 
human HLA-DM Map.DM1 L. Denzin 
mouse CLIP/I-Ab 15G4 L. Denzin 
mouse Ea52-68/I-Ab YAe Thermo Fisher 
mouse CD80 16-10A1 BD 
mouse CD86 GL1 BD 
mouse ICAM-1 (CD54) YN1/1.7.4 Biolegend 
mouse CD45.1 A20 Biolegend 
mouse CD45.2 104 Biolegend 
influenza hemagglutinin (HA) IC5-4F8 BEI 
influenza nucleoprotein (NP) D67J Thermo Fisher 
mouse CD44 IM7 Biolegend 
mouse CD62L MEL-14 Biolegend 
mouse CD69 H1.2F3 Biolegend 
mouse CD11a M17/4 Biolegend 
mouse PD1 RMP1-30 Biolegend 
mouse LAG3 C9B7W Biolegend 
mouse Foxp3 FJK-16s Thermo Fisher 
mouse Ki67 16A8 Biolegend 
mouse IL5 TRFK5 Biolegend 
mouse IL13 eBio13A Thermo Fisher 
mouse IL17 TC11-18H10.1 Biolegend 
mouse IFNg XMG1.2 Biolegend 
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